

Received Date : 03-Mar-2016

Revised Date : 11-Jul-2016

Accepted Date : 09-Aug-2016

Article type : Original Article

What is the evidence-base for atopic eczema treatments? A summary of published randomised controlled trials

H. Nankervis¹, K.S. Thomas¹, F.M. Delamere¹, S. Barbarot¹, S. Smith¹, N.K. Rogers¹ and H.C. Williams^{1*}

¹Centre of Evidence Based Dermatology, University of Nottingham, King's Meadow Campus, Lenton Lane, Nottingham, NG7 2NR

***Corresponding author:** Hywel C. Williams; Centre of Evidence Based Dermatology, University of Nottingham, King's Meadow Campus, Lenton Lane, Nottingham, NG7 2NR. Email: hywel.williams@nottingham.ac.uk

Funding:

This publication presents independent research funded by the National Institute for Health Research (NIHR) under its Programme Grants for Applied Research Programme (RP-PG-0407-10177). The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health.

SB received a grant from Le Collège des Enseignants en Dermatologie de France (CEDEF) to support his work on this project in his role as visiting Fellow at the Centre of Evidence Based Dermatology

Conflict of interest disclosures:

SB has received grants from Pierre Fabre Laboratory, personal fees from GlaxoSmithKline and Sinclair Pharma and grants and personal fees from Astellas.

HCW is Director of the NIHR Health Technology Assessment programme.

KST and HCW are authors on two of the trials included in this review.

All other authors: nothing to disclose.

Keywords: eczema, atopic dermatitis, treatment, systematic review

What's already known about this topic?

- The evidence base for atopic eczema (AE) treatments is broad and limited by poor quality trials
- The last systematic review to provide an overview of all published AE randomised controlled trials (RCTs) was conducted in 2000

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1111/bjd.14999

This article is protected by copyright. All rights reserved.

What does this study add?

- Over 500 RCTs have been published on treatments for AE, but many research gaps remain
- This summary highlights treatment for which there is reasonable evidence of benefit, and those for which there is reasonable evidence of no benefit
- Future research priorities that have no current RCT evidence include the role of allergy testing (followed by allergen avoidance), and modified bathing habits in the management of AE

Summary (Abstract)

Atopic eczema (AE) is a common chronic inflammatory skin condition. Whilst many AE treatment options are available, the evidence to support their efficacy varies in depth and quality. In 2000, an NIHR HTA systematic review identified and evaluated existing randomised controlled trials (RCTs) of AE treatments. To ensure continuing utility, the NIHR commissioned an update to the review. Here, we present an overview of the updated report and key findings.

Systematic reviews and RCTs of AE treatments that included participants with AE (criteria based or diagnosed) were identified using: MEDLINE, EMBASE, CENTRAL, LILACS, AMED, CINAHL and Cochrane Skin Group Specialised Register (searched to August 31st 2013 (RCTs) and 31st December 2015 (systematic reviews)). Outcome measures included: symptoms, AE severity, quality-of-life, and adverse effects. Study quality was assessed using the Cochrane Collaboration risk of bias tool.

Of the 287 new RCTs identified, only 22 (8%) were judged to be low risk of bias. When combined with RCTs from the previous review (n= 254), we found 'reasonable evidence of benefit' for corticosteroids, calcineurin inhibitors, AtopiclairTM, ciclosporin, azathioprine, ultraviolet light and education programmes.

Interventions with reasonable evidence of 'no benefit' included some dietary interventions, ion exchange water softeners, multiple daily applications of topical corticosteroids and antibiotic-containing corticosteroids for non-infected AE. Many common treatments lack evidence of efficacy and warrant further evaluation.

The evidence base for AE is still hampered by poor trial design and reporting. The trials included in this review were used to establish the Global Resource of Eczema Trials (GREAT) Database.

Introduction

Atopic eczema (AE) (syn. atopic dermatitis), is a chronic inflammatory skin condition characterised by an itchy red rash that affects all age groups¹. AE has one of the highest burdens compared to other skin diseases.²

The evidence-base for AE treatments is extensive, but has limitations in terms of quality and relevance.³ This is exemplified by the 'Systematic Review of Treatments for Atopic Eczema', published by the National Institute for Health Research (NIHR), which identified 254 RCTs of AE treatment covering 47 interventions.⁴ The

encompassing nature of the review, and critical appraisal of the evidence therein, has helped to inform clinical guidelines on an international level for over a decade and the report has been heavily cited, with more than 650 citations listed in Google Scholar at time of writing.⁵⁻⁸

To ensure its continuing utility, the NIHR commissioned an update of the systematic scoping review as part of a programme of work on the prevention and treatment of skin disease,⁹ with the aim of summarising the evidence-base for AE treatments for guideline writers, healthcare professionals and patients. This review will also help in identifying research gaps to be addressed in the future, and in identifying topics suitable for specific targeted systematic reviews.

The current paper provides a summary of the updated scoping review (which is freely available through the NIHR Journal series)⁹, with a specific focus on the overall findings and conclusions.

Methods used for the scoping review

The following section briefly described the methodology employed to create the scoping review, which can be viewed in its entirety in the methods section of the full report.⁹

Design

This was a systematic scoping review of all systematic reviews and randomised controlled trials (RCTs) for AE treatments. A scoping review attempts to systematically map existing evidence on a given topic and identify potential gaps in the literature to inform future research priorities. It differs from a clinically-focussed systematic review in that it often covers a much broader topic area, summarises the evidence in a qualitative format and offers limited critical appraisal.¹⁰

Type of studies included

As systematic reviews and RCTs represent the best source of unbiased evidence on the effectiveness of treatments, we only included these types of studies. Studies were required to contain at least one clinical outcome. Prevention studies, provocation studies, changes in blood biochemistry and evaluations of cellular mechanisms were excluded.

Participants

Studies were included if participants (of any age) had AE, as diagnosed by a physician, or that met with a diagnostic criteria (e.g. Hanifin and Rajka,¹¹ UK working party¹² or similar).

Main outcome measures

Outcome measures chosen for the review were deliberately broad, in order to reflect those commonly used in AE trials.^{13,14} Changes in patient-rated symptoms such as itching (pruritus) or sleep loss were extracted where possible. Global severity, as rated by patients or their physician, was also sought. Other outcomes included

changes in AE severity rating scales; quality of life; and adverse events (encompassing adverse events and adverse reactions depending on how these were reported in the original RCTs).

Search strategy

We searched the following electronic databases (search dates end of 1999 to 31st August 2013) - MEDLINE; EMBASE; CENTRAL; The Cochrane Skin Group Specialised Trials Register; Latin American and Caribbean Health Sciences database (LILACS); Allied and Complementary Medicine Database (AMED); Cumulative Index to Nursing and Allied Health Literature (CINAHL) (Supplementary Figure 1). We also searched www.controlled-trials.com for completed and ongoing RCTs using the terms atopic dermatitis, atopic eczema and eczema as well as using our extensive contacts in the field of AE research to identify other ongoing studies.

Systematic reviews on AE treatments were searched for up until Dec 2015 using PubMed, EMBASE, the Cochrane Library and NHS Evidence. Where appropriate the results of these specific systematic reviews are presented alongside the RCT evidence.

We used the following disease terms for AE: atopic dermatitis, atopic eczema, eczema, neurodermatitis, infantile eczema, childhood eczema, or Besniers' prurigo. No language restrictions were applied; data from non-English papers was extracted by international colleagues. References were screened by one author (either SS or HN), with discussion with a second author as required (HW, KT or SB). Those studies using terms that were definitely not AE, such as allergic contact eczema, were excluded. Terms that were considered possibly AE, such as 'childhood eczema', were scrutinised and only included if the description of the participants clearly indicated AE.

Data assessment and study quality

Data was independently extracted by two authors (HN and SB or SS) with discrepancies resolved by consensus or by an arbitrator (HCW, KST or FMD). Although primarily a scoping review, trial quality (specifically randomisation, allocation concealment and blinding) was evaluated. This was done using Cochrane collaboration's risk of bias assessment tool.¹⁵ The overall risk of bias for the included studies was summarised according to defined criteria (Supplementary Table 1). Authors were not blinded to the identity of the RCT authors, and a more detailed quality assessment (such as GRADE¹⁶) was unfeasible given the number of included studies.

Presentation of the results

Results are presented according to broad categories of treatments: i) topical corticosteroids and topical immunomodulators; ii) emollients and other topical treatments (including bath additives and oils); iii) antimicrobials including antibiotics, antiseptics and antifungals; iv) antihistamines and mast cell stabilisers; v) dietary interventions (including probiotics, essential fatty acids, vitamins, cows' milk substitutes); vi) non-pharmacological interventions (including education, psychological therapies, different ways of providing AE care, allergen avoidance followed by allergen avoidance or re-introduction and medical devices); vi)

phototherapy; vii) systemic immunomodulatory agents; viii) complementary therapies (homeopathy, aromatherapy, hypnotherapy, Chinese herbal medicine, St John's Wort, acupuncture, balneotherapy, relaxation); ix) other.

For clarity of interpretation, results are also summarised according to categories of evidence:

- i) treatments for which there is reasonable *evidence of benefit*
- ii) treatments for which there is reasonable evidence of *no-clinically useful benefit*
- iii) treatments for which there is *insufficient evidence to inform clinical decision-making*
- iv) treatments with an *absence of RCT evidence*.

Classification of treatment options into these four categories was a qualitative judgement on the part of the authors based on availability and quality of the evidence, and the likelihood of clinically important effects. It is not intended to signify that all uncertainty has been resolved in those areas classed as having reasonable evidence of benefit or reasonable evidence of no benefit – simply that there is a reasonable body of evidence that may usefully inform clinical decision-making. In this paper, we have not tried to summarise the possible harms of all included studies, but harms and drawbacks of treatments are included for all treatment categories in the main report.

Pooling of the trial results using meta-analysis was not possible due to the very wide nature of interventions included, and the very heterogeneous nature of study participants and outcomes. However, interventions with evidence of benefit or evidence of no benefit have been mapped to the latest relevant systematic reviews on these topics where they exist.

Results of the review

Summary of trials

In addition to the 254 RCTs identified in the original 2000 scoping review, this updated includes an additional 287 new RCTs, making 541 RCTs in total covering 92 different interventions for treating AE. The number of RCTs published according to broad treatment categories is shown (Figure 1), with further details provided in Supplementary Figure 2.

The size of the newly identified RCTs varied widely from seven randomised participants to 972 participants. Most of the trials were conducted in secondary care, and tended to include participants with either moderate to severe disease, or mild to moderate disease. Very few RCTs included all severities of AE.

Reporting was generally poor, with “unclear” categories dominating the assessments: randomisation method (2% high, 36% low and 62% unclear risk of bias), allocation concealment (3% high, 15% low and 82% unclear risk of bias), and blinding or masking of the intervention (15% high, 28% low, 57% unclear risk of bias). Only 22/287 (8%) were considered to be at low risk of bias for all three quality criteria (randomisation, allocation

concealment and blinding). Overall agreement between the team members on the availability and quality of the evidence, and the likelihood of clinically important effects was good.




Figure 1: Number of included RCTs per treatment category

Treatments with reasonable evidence of benefit

Fourteen interventions or treatment approaches were felt to have reasonable evidence of benefit (Table 1). These include the use of topical corticosteroids and topical calcineurin inhibitors, both for the treatment of active AE, and as intermittent proactive (maintenance) therapy for the prevention of AE flares. Other interventions including AtopiclairTM emollient, ultraviolet light therapy, azathioprine and ciclosporin, all had reasonable evidence of benefit compared to placebo/vehicle. Similarly, RCT and systematic review evidence suggested that education may be beneficial, although the exact components of a successful education programme in different clinical settings is still unclear.

Of the 14 interventions with reasonable evidence of benefit, 10/14 (71%) have been the subject of more detailed, treatment-specific systematic reviews (Table 1).

Treatments with evidence of no clinically useful benefit

Nine interventions were deemed to have a reasonable level of evidence of no benefit in treating AE (Table 2): topical corticosteroids containing an antibiotic for the treatment of AE that is not infected; *Mycobacterium vaccae* vaccine; probiotics; ion exchange water softeners; evening primrose oil and borage oil.

Treatments which require more research

There are many treatments for AE that have insufficient or contradictory RCT evidence, for which further research is required (Table 3). Some of the treatments have been trialled many times, however, the quality of reporting means that evidence for these treatments is not yet strong enough.

Treatments with an absence of RCT evidence

The scoping review has helped to identify areas for which there is currently no RCT evidence for commonly used practices for the treatment of AE including: dilution of topical corticosteroids, order of application of topical corticosteroids and emollients, impregnated bandages (zinc or ichthammol paste bandages), modified bathing habits (non-antiseptic bath additives, soap avoidance, frequency of bathing), and the role of routine allergy testing followed by allergen avoidance or re-introduction.

Discussion

Main findings

The systematic scoping review findings indicated there were only a small number of treatments with evidence of benefit (Table 1) and some treatments with evidence of no benefit (Table 2). For the majority of treatments, however, further but better designed research is needed (see Table 3). It is disappointing that there was a lack of strong evidence base for some of the most widely used AE treatments, such as emollients and bandages. However, stopping or restricting the use of these treatments on the basis of lack of RCT evidence would not benefit patients. Although information on treatment drawbacks and harms are included for each intervention in the main review, we have not tried to summarise them in this report due to their diverse and treatment-specific nature. Generally, harms were reported less well than treatment benefits resulting in an asymmetry of information to inform patient choices.

In addition to the established approach for treating AE flares with topical corticosteroids, perhaps the single largest advance in AE treatment since the 2000 review has been the strong evidence supporting the value of a proactive approach for maintaining AE remission through the use of twice weekly topical corticosteroids or calcineurin inhibitors.¹⁷ Educational approaches have also emerged as a potentially promising intervention, although further work is needed to establish the most important components of the intervention, and the most cost-effective ways of delivering education in different health settings.

The finding that Atopiclair™ emollient has emerged as a potentially useful intervention for AE in four out of five industry-sponsored trials is difficult to interpret at this time. High-quality, independent trials are now needed that compare Atopiclair™ to other commonly used (and cheaper) emollients.

The understanding that some interventions now have sufficient evidence to suggest little or no benefit for AE patients is equally important. These interventions provide options for disinvestment, ensuring that available funds are channelled to the most effective treatments. Possible areas to consider for disinvestment include: the application of topical corticosteroids twice a day, as once-daily application has been shown to be equally effective; topical corticosteroids containing antibiotics when used for the management of non-infected AE; use of ion exchange water softeners; and dietary supplements (probiotics, borage oil, evening primrose oil).

Implications for research

There is a lack of AE treatment trials conducted in a primary care setting, where most patients are seen. The research questions being investigated often fail to reflect the most pressing questions for clinicians and patients. A recent James Lind Alliance Priority Setting Partnership³ identified the most important treatment uncertainties as judged by patients and clinicians. When set in the context of the updated evidence base from the review, the following areas identified from the Priority Setting Partnership seem to be most pressing:

Priority areas with no current RCT evidence

- What role might allergy tests play in treating AE?
- What is the best way for people with AE to wash?
- Which should be applied first when treating AE – emollients or topical corticosteroids?

Priority areas with limited RCT evidence

- What is the best and safest way of using topical corticosteroids for AE?
- What is the long-term safety of applying topical steroids to the skin for AE?
- Which emollient is the most effective and safe in treating AE?
- What is the best psychological treatment for itching/scratching in AE?
- What are the best and safest 'natural' products to apply to the skin?
- How much does avoidance of irritants and allergens help people with AE?
- What is the role of diet in treating AE (exclusion diets and nutritional supplements)
- Which is more effective in the management of AE: education programmes, GP care, nurse-led care, dermatology-led care of multi-disciplinary teams?
- Which is safer and more effective in treating AE: topical corticosteroids or calcineurin inhibitors (especially for proactive flare prevention)?
- How effective are interventions to reduce skin infections in the management of AE?
- What is the best and safest way of using drugs that suppress the immune system (particularly in children)

Some important topics have already been picked up by NIHR funding bodies, and large pragmatic trials are currently underway in the UK evaluating the role of topical and oral antibiotics for the treatment of infected AE (CREAM) (UKCRN ID 11233), silk clothing for the management of moderate to severe AE (CLOTHES) (UKCRN ID 15132), the role of bath emollients in the management of AE (BATHE: UKCRN ID 17348) and a feasibility trial of emollient clinical and cost effectiveness (COMET: UKCRN ID 16571).

Methodological research

One of the most pressing concerns identified by this review is the continued preponderance of small, poorly reported and poorly conducted trials. Greater efforts to work collaboratively to conduct large, well designed studies that address important questions, can only be of benefit to patients and healthcare providers.

Similarly, the ability to combine study results in meta-analysis continues to be hampered by the wide variation in outcome measures used. The move towards using the same core outcome sets as encouraged by the Harmonising Outcome Measures for Eczema (HOME) initiative¹⁸⁻²⁰ (www.homeforeczema.org) are likely to be beneficial for future clinical interpretation and evidence syntheses.

Strengths and limitations of the review

The updated review has used a clear methodology for identifying RCTs for inclusion, which has minimised potential selection bias. However, despite searching the main bibliographic databases (MEDLINE and EMBASE) and several smaller, specialist databases (CINAHL, AMED and LILACS), it is possible that we might have missed some RCTs. Many of the treatments that are lacking in RCT evidence have nevertheless been studied using uncontrolled designs, which may provide additional useful information. Similarly, large cohort studies are required to detect rare treatment adverse effects.

Whilst masking the identity of the trial authors from the review team was not practical, this may have introduced bias when summarising qualitative aspects of the results. Given the very wide scope of the review and heterogeneous nature of participants, interventions and outcomes, it was not practical to undertake detailed meta-analysis for single interventions. These will need to be conducted (where appropriate) within much narrower intervention-specific systematic reviews in the future.

Our classification of treatment options into categories such as “evidence of benefit to support” is not tantamount to a positive recommendation for widespread use or otherwise, as that is the remit of guideline developers and depends on factors such as magnitude of benefit, adverse effects, how the treatment compares with existing active treatments, availability, cost effectiveness and population most likely to benefit. As with all systematic reviews, the evidence presented will become out of date quite rapidly for some topics, and readers of the review are also directed to our free to access database of AE RCTs Global Resource of Eczema Trials (GREAT Database, accessible at <http://www.greatdatabase.org.uk>), which contains details of all the studies in the scoping review and can be used by readers who wish to investigate particular included or excluded studies further.

Conclusion

The number of RCTs for AE has increased substantially since the year 2000⁴ yet most are still small, poorly reported, and do not address questions of clinical importance to patients and healthcare professionals

We hope that our work provides an easily accessible guide for patients and clinicians wishing to research treatment effects, and that it will be used by guideline developers to prevent duplication of effort in collating and evaluating the available evidence base for AE treatments. AE researchers will be able to identify potential research gaps and systematic reviews that require further work.

Table and figure legends

Figure 1: Number of included RCTs per treatment category

Table 1: Treatments with reasonable evidence of benefit for AE patients

Table 2: Treatments with reasonable evidence of no benefit for AE patients

Table 3: Treatments which require more research

Supplementary Figure 1: Search strategy used to identify trials

Supplementary Table 1: Criteria used for discussing the risk of bias in the summaries of treatment categories

Table 1: Treatments with reasonable evidence of benefit for AE patients

Evidence of benefit: at least one good quality RCT or a large body of evidence and a clinically useful finding. We defined a 'good quality' trial as well designed and well reported and with a magnitude of benefit deemed by the authors to be clinically relevant, and 'large body of evidence' as enough trials with consistent evidence of clinically relevant benefit, despite some limitations in reporting					
Intervention and severity of AE	Population	Trials (n)	Participants (n)	Risk of bias	Systematic Review(s)
Topical Corticosteroids					
Corticosteroids (various strengths) are superior to vehicle for AE of all severities	Adults and children	23 ²¹⁻⁴²	3857	Mostly unclear	None
Topical Calcineurin Inhibitors					
Pimecrolimus (1%) is superior to vehicle for mild to moderate AE	Mainly children	16 ⁴³⁻⁵⁷	3149	Mostly unclear	Chen (2011) ⁵⁸ Number of included studies: 6 (<18 years only) Meta-analysis: OR 3.21, 95% CI 2.48 to 4.14
Tacrolimus (0.03, 0.1, 0.3%) is superior to vehicle for moderate to severe AE	Adults and children	9 ⁵⁹⁻⁶⁵	2089	Mostly unclear	Chen (2011) ⁵⁸ Number of included studies: 4 (<18 years only) Meta-analysis: OR 4.56, 95% CI 2.80 to 7.44
Tacrolimus (0.03, 0.1%) is superior to hydrocortisone acetate (1%) for moderate-to severe AE	Children	2 ^{66,67}	1184	Unclear	Martins (2015) ⁶⁸ Number of included studies: 2 Tacrolimus 0.03%: RR 2.58, 95% CI 1.96 to 3.38 Number of included studies:1 Tacrolimus 1%: RR 3.09, 95% CI 2.14 to 4.45
Tacrolimus (0.1%) superior to fluticasone propionate ointment (0.005%) for moderate to severe facial AE	Adults	1 ⁶⁹	568	Mostly unclear	<i>Not applicable</i>
Tacrolimus (0.1, 0.03%) is superior to pimecrolimus (1%) for AE of all severities	Adults and children	5 ^{70-72*}	1243	Mostly low	Martins (2015) ⁶⁸ Number of included studies: 3 Meta-analysis: RR 1.80, 95% CI 1.35 to 2.42
Proactive (maintenance) topical therapy for preventing flares					
Corticosteroids applied twice a week are superior to vehicle for moderate to severe AE	Adults and children	4 ⁷³⁻⁷⁶	929	Mostly unclear	Schmitt (2011) ¹⁷ Number of included studies: 4 Meta-analysis: RR 0.46, 95% CI 0.38-0.55
Tacrolimus (0.1, 0.03%) applied twice a week is superior to vehicle for mild to severe AE	Adults and children	4 ⁷⁷⁻⁸⁰	741	Mostly unclear	Schmitt (2011) ¹⁷ Number of included studies: 3 Meta-analysis: RR 0.78, 95% CI 0.60-1.00
Pimecrolimus (1%) applied twice a week is superior to vehicle for AE of all severities	Mainly children	2 ^{44,81}	251	Mostly low	None
Systemic Therapies					
Ciclosporin superior to placebo for severe AE	Adults	4 ⁸²⁻⁸⁵	113	Mostly unclear	Schmitt 2007 ⁸⁶ Number of included studies: 12 Meta-analysis: Included non-RCTs
Azathioprine superior to placebo for moderate to severe AE	Adults	2 ^{87,88}	100	Mostly low	Schram 2011 ⁸⁹ Number of included studies: 2 Meta-analysis: not done
Ultra-violet Light Therapy					
NB-UVB superior to placebo (visible light) for moderate to severe AE	Adults	2 ^{90,91}	116	Mostly unclear	Dogra 2015 ⁹² Number of included studies: 13 (included non-RCTs) Meta-analysis: not done Gambichler 2005 ⁹³ Number of included studies: 3 (included non-RCTs) Meta-analysis: not done
Other					
Atopiclair™ superior to vehicle for mild to moderate AE	Adults and children	4 ⁹⁴⁻⁹⁸	489	Mixed	None
Education superior to no-education for moderate to severe AE	Mainly children	7 ⁹⁹⁻¹⁰⁵	1076	Mixed	Ersner 2014 ¹⁰⁶ Number of included studies:10 Meta-analysis: not done

* Please note, 3 studies were included within one paper

Table 2: Treatments with reasonable evidence of no benefit for AE patients

Evidence of no benefit: at least one good quality RCT or several less well reported RCTs which consistently failed to show a convincing benefit on overall disease activity. We defined a 'good quality' trial as well designed and well reported, and large enough to exclude a clinically useful benefit or several trials with no evidence of benefit to give confidence in there being no clinically relevant benefit, despite less clear reporting					
Intervention and severity of AE	Population	Trials (n)	Participants (n)	Risk of bias	Systematic Review(s)
Twice daily versus once daily topical corticosteroids	Adults and children	3 ^{34,107,108}	617	Mostly unclear	Green (2005) ¹⁰⁹ Number of included studies: 10 Meta-analysis: not preformed (heterogeneity)
Antibiotic-containing corticosteroids versus corticosteroids alone for mild to severe non-infected AE	Mainly unspecified	5 ¹¹⁰⁻¹¹⁴	352	Mostly unclear	Bath-Hextall (2010) ¹¹⁵ Number of included studies: 2 Meta-analysis: RR 0.52, 95% CI 0.23 to 1.16
Probiotics for treating AE versus placebo	Mainly children	20 ¹¹⁶⁻¹³⁵	1513	Mostly unclear	Boyle (2009) ¹³⁶ Number of included studies: 5 Meta-analysis: mean difference -0.90, 95% CI -2.84 to 1.04
Dietary supplements rich in linoleic acid (evening primrose oil and borage oil) versus placebo	Mainly adults	23 ¹³⁷⁻¹⁵⁸	1448	Mostly unclear	Bamford (2013) ¹⁵⁹ Number of included studies: evening primrose oil (7 trials) Meta-analysis for Evening Primrose Oil mean difference -2.22, 95% CI -10.48 to 6.04. Number of included studies: borage oil (8 trials) Meta-analysis for borage oil: not preformed (heterogeneity)
Protease inhibitor SRD441 versus vehicle in for mild to moderate AE	Adults	1 ¹⁶⁰	93	Mostly low	SR not applicable
Emollient with furfuryl palmitate versus emollient alone for mild to moderate AE	Children	1 ¹⁶¹	117	Low	SR not applicable
Ion exchange water softening devices versus no water softening for moderate to severe AE	Children	1 ¹⁶²	336	Low	SR not applicable
Cipamfylline cream versus vehicle	Adults	1 ¹⁶³	103	Mostly low	SR not applicable
Mycobacterium vaccae vaccine versus no vaccine for moderate to severe AE	Mainly children	4 ¹⁶⁴⁻¹⁶⁷	372	Low	None

Table 3: Treatments which require more research

Intervention	Number of trials	Number of participants
Emollients	20 ¹⁶⁸⁻¹⁸⁶	1664
Dietary interventions including prebiotics, dietary restrictions, and synbiotics	13 ¹⁸⁷⁻¹⁹⁹	711
Non-pharmacological interventions, including: specialised clothing (silk or synthetic fibres with or without antibiotics); environmental interventions (house dust mite reduction, desensitisation); staying in a different climate; different approaches to organisation of care such as additional visits to the doctors or nurse led clinics; support groups; e-health management; psychological therapies (stress reduction or habit reversal techniques); balneotherapy (salt baths); biofeedback	33 ²⁰⁰⁻²³²	2447
Oral antibiotics for clinically infected or uninfected AE	3 ²³³⁻²³⁵	125
Topical corticosteroids combined with topical antibiotics for infected AE	2 ^{110,236}	660
Wet wraps in addition to topical corticosteroids	5 ²³⁷⁻²⁴¹	153
Antiseptic and non-antiseptic bath additives	4 ²⁴²⁻²⁴⁵	97
Systemic and topical antifungals	4 ²⁴⁶⁻²⁴⁹	202
Topical treatments including: topical vitamin B12; topical coal tar; camellia oil; SRD441 (protease inhibitor); WBI-1001 (an inhibitor of T cell inflammatory cytokine secretion); hippophae rhamnoides; black seed oil; pill mask; rosmarinic acid; vitreoscilla filiformis; shale oil; miltefosine; opiate receptor antagonist; carbohydrate derived fulvic acid; raffinose; farnesol and xylitol, bacterial antigens; camomile extract; heparin and levomenol; 15(R/S)-Methyl-lipoxin A4, N-acetyl-l-hydroxyproline; nalmeferne hydrochloride monohydrate (SRD174)	27 ²⁵⁰⁻²⁷⁶	1340
Systemic treatments including: oral prednisolone; methotrexate; mycophenolate mofetil; biological therapies (omalizumab; mepolizumab); intravenous immunoglobulin; montelukast	22 ²⁷⁷⁻²⁹⁸	900
Oral antihistamines	29 ^{297,299-326}	4201
Other less commonly used interventions including: oral pimecrolimus; oral naltrexone; autologous blood therapy; tandospirone citrate; full spectrum light therapy; excimer laser; nitrazepam; theophylline; topical salbutamol; papaverine and suplastat tosilate	14 ³²⁷⁻³³⁸	481
Complementary therapies including: Chinese Herbal treatment; hypnotherapy; massage therapy; aromatherapy; acupuncture; acupressure; and other herbal treatments	17 ³³⁹⁻³⁵⁴	604

1. Friedmann PS, Holden CA. Atopic dermatitis. In: Burns DA, Braethnach SM, Cox N, Griffiths CE, eds. *Rook's Textbook of Dermatology*. 7th ed: Blackwell Publishers; 2004.
2. Hay RJ, Johns NE, Williams HC, et al. The global burden of skin disease in 2010: an analysis of the prevalence and impact of skin conditions. *The Journal of investigative dermatology*. Jun 2014;134(6):1527-1534.
3. Batchelor JM, Ridd MJ, Clarke T, et al. The Eczema Priority Setting Partnership: a collaboration between patients, carers, clinicians and researchers to identify and prioritize important research questions for the treatment of eczema. *Br J Dermatol*. Mar 2013;168(3):577-582.
4. Hoare C, Li Wan Po A, Williams H. Systematic review of treatments for atopic eczema. *Health Technol Assess*. 2000;4(37):1-191.
5. NICE. *Atopic Eczema in Children: Management of atopic eczema in children from birth up to the age of 12 years*. London. 2007.
6. SIGN. Scottish Intercollegiate Guidelines Network. Management of atopic eczema in primary care. . 2011;SIGN publication no. 125.
7. Katayama I, Kohno Y, Akiyama K, et al. Japanese Guideline for Atopic Dermatitis 2014. *Allergology international : official journal of the Japanese Society of Allergology*. Sep 2014;63(3):377-398.
8. Sidbury R, Tom WL, Bergman JN, et al. Guidelines of care for the management of atopic dermatitis: Section 4. Prevention of disease flares and use of adjunctive therapies and approaches. *Journal of the American Academy of Dermatology*. Dec 2014;71(6):1218-1233.
9. Nankervis H, Thomas KS, Delamere FM, et al. Scoping systematic review of treatments for eczema. *Programme Grants for Applied Research*. May 2016.
10. Armstrong R, Hall BJ, Doyle J, et al. Cochrane Update. 'Scoping the scope' of a cochrane review. *Journal of public health (Oxford, England)*. Mar 2011;33(1):147-150.
11. Hanifin JM, Rajka G. Diagnostic Features of Atopic-Dermatitis. *Acta Derm-Venereol*. 1980 1980;92:44-47.
12. Williams HC, Burney PGJ, Hay RJ, et al. The U.K. Working Party's Diagnostic Criteria for Atopic Dermatitis. I. Derivation of a minimum set of discriminators for atopic dermatitis. *Br J Dermatol*. Sep 1994;131(3):383-396.
13. Rehal B, Armstrong AW. Health outcome measures in atopic dermatitis: a systematic review of trends in disease severity and quality-of-life instruments 1985-2010. *PloS one*. 2011;6(4):e17520.
14. Schmitt J, Langan S, Williams HC, et al. What are the best outcome measurements for atopic eczema? A systematic review. *The Journal of allergy and clinical immunology*. Dec 2007;120(6):1389-1398.
15. Higgins J, Green S. Cochrane Handbook for Systematic Reviews of Interventions 2011; Version 5.1.0 www.cochrane-handbook.org.
16. Atkins D, Best D, Briss PA, et al. Grading quality of evidence and strength of recommendations. *BMJ (Clinical research ed.)*. Jun 19 2004;328(7454):1490.

17. Schmitt J, von Kobyletzki L, Svensson A, et al. Efficacy and tolerability of proactive treatment with topical corticosteroids and calcineurin inhibitors for atopic eczema: systematic review and meta-analysis of randomized controlled trials. *Br J Dermatol*. Feb 2011;164(2):415-428.
18. Schmitt J, Spuls P, Boers M, et al. Towards global consensus on outcome measures for atopic eczema research: results of the HOME II meeting. *Allergy*. Sep 2012;67(9):1111-1117.
19. Chalmers JR, Schmitt J, Apfelbacher C, et al. Report from the third international consensus meeting to harmonise core outcome measures for atopic eczema/dermatitis clinical trials (HOME). *Br J Dermatol*. Dec 2014;171(6):1318-1325.
20. Spuls P. Report from the fourth international consensus meeting to harmonise core outcome measures for atopic eczema/dermatitis clinical trials (HOME initiative) (at peer review). 2016.
21. Paller AS, Nimmagadda S, Schachner L, et al. Fluocinolone acetonide 0.01% in peanut oil: therapy for childhood atopic dermatitis, even in patients who are peanut sensitive. *Journal of the American Academy of Dermatology*. 2003 Apr 2003;48(4):569-577.
22. Eichenfield LF, Miller BH, Cutivate Lotion Study G. Two randomized, double-blind, placebo-controlled studies of fluticasone propionate lotion 0.05% for the treatment of atopic dermatitis in subjects from 3 months of age. *Journal of the American Academy of Dermatology*. 2006 Apr 2006;54(4):715-717.
23. Hebert AA, Cook-Bolden FE, Basu S, et al. Safety and efficacy of desonide hydrogel 0.05% in pediatric subjects with atopic dermatitis. *Journal of drugs in dermatology : JDD*. 2007 2007;6(2):175-181.
24. Pellanda C, Weber M, Bircher A, et al. Low-dose triamcinolone acetonide in the phytocosmetic lichtena reduces inflammation in mild to moderate atopic dermatitis. *Dermatology (Basel, Switzerland)*. 2005 2005;211(4):338-340.
25. Abramovits W, Oquendo M. Hydrocortisone butyrate 0.1% lipocream in pediatric patients with atopic dermatitis. *Skinmed*. 2010(2):72-79. <http://www.mrw.interscience.wiley.com/cochrane/clcentral/articles/219/CN-00749219/frame.html>.
26. Matheson R, Kempers S, Breneman D, et al. Hydrocortisone butyrate 0.1% lotion in the treatment of atopic dermatitis in pediatric subjects. *Journal of drugs in dermatology : JDD*. 2008 2008;7(3):266-271.
27. Del Rosso JQ, Bhambri S, Del Rosso JQ, et al. Daily application of fluocinonide 0.1% cream for the treatment of atopic dermatitis. *The Journal of Clinical & Aesthetic Dermatology*. Sep 2009;2(9):24-32.
28. Breneman D, Fleischer ABJ, Kaplan D, et al. Clobetasol propionate 0.05% lotion in the treatment of moderate to severe atopic dermatitis: a randomized evaluation versus clobetasol propionate emollient cream. *Journal of Drugs in Dermatology*. 2005 2005;4(3):330-336.
29. Woods MT, Brown PA, Baig-Lewis SF, et al. Effects of a novel formulation of fluocinonide 0.1% cream on skin barrier function in atopic dermatitis. *Journal of drugs in dermatology : JDD*. Feb 2011;10 (2):171-176.
30. Brock W, Cullen SI. Triamcinolone acetonide in flexible collodion for dermatologic therapy. *Archives of Dermatology*. 1967;96(2):193-194.
31. Gehring W, Gloor M. Treatment of the atopic dermatitis with a water-in-oil emulsion with or without the addition of hydrocortisone - Results of a controlled double-blind randomized study using clinical evaluation and bioengineering methods. [German]. *H+G Zeitschrift fur Hautkrankheiten*. 1996;71 (7):554-560.
32. Vanderploeg DE. Betamethasone dipropionate ointment in the treatment of psoriasis and atopic dermatitis: a double blind study. *Southern Medical Journal*. 1976;69 (7):862-863.
33. Roth HL, Brown EP. Hydrocortisone valerate. Double-blind comparison with two other topical steroids. *Cutis*. 1978;21 (5):695-698.
34. Sudilovsky A, Muir JG, Bocobo FC. A comparison of single and multiple applications of halcinonide cream. *International Journal of Dermatology*. 1981;20 (9):609-613.
35. Lupton ES, Abbrecht MM, Brandon ML. Short-term topical corticosteroid therapy (halcinonide ointment) in the management of atopic dermatitis. *Cutis; cutaneous medicine for the practitioner*. 1982;30 (5):671-675.
36. Sefton J, Loder JS, Kyriakopoulos AA. Clinical evaluation of hydrocortisone valerate 0.2% ointment. *Clinical Therapeutics*. 1984;6 (3):282-293.
37. Wahlgren CF, Hagermark O, Bergstrom R, et al. Evaluation of a new method of assessing pruritus and antipruritic drugs. *Skin Pharmacology*. 1988;1 (1):3-13.
38. Stalder JF, Fleury M, Sourisse M, et al. Local steroid therapy and bacterial skin flora in atopic dermatitis. *British Journal of Dermatology*. 1994;131(4):536-540.
39. Lebwohl M. Efficacy and safety of fluticasone propionate ointment, 0.005%, in the treatment of eczema. *Cutis; cutaneous medicine for the practitioner*. 1996;57 (2 Suppl):62-68.
40. Lebwohl M, Lane A, Savin R, et al. A comparison of once-daily application of mometasone furoate 0.1% cream compared with twice-daily hydrocortisone valerate 0.2% cream in pediatric atopic dermatitis patients who failed to respond to hydrocortisone. *International Journal of Dermatology*. 1999;38(8):604-606.
41. Sears HW, Bailer JW, Yeadon A. Efficacy and safety of hydrocortisone buteprate 0.1% cream in patients with atopic dermatitis. *Clinical Therapeutics*. 1997;19(4):710-719.
42. Maloney J, Morman MR, Stewart DM, et al. Clobetasol propionate emollient 0.05% in the treatment of atopic dermatitis. *International Journal of Dermatology*. 1998;37 (2):142-144.
43. Salavec M, Buckova H. First experiences with 1% Pimecrolimus cream therapy in prevention of atopic eczema flares in children (Czechoslovakian). *Cesko-slovenska dermatologie*. 2004 2004;79(1):3-7.

44. Zuberbier T, Heinzerling L, Bieber T, et al. Steroid-sparing effect of pimecrolimus cream 1% in children with severe atopic dermatitis. *Dermatology (Basel, Switzerland)*. 2007 2007;215(4):325-330.
45. Sigurgeirsson B, Ho V, Ferrandiz C, et al. Effectiveness and safety of a prevention-of-flare-progression strategy with pimecrolimus cream 1% in the management of paediatric atopic dermatitis. *Journal of the European Academy of Dermatology & Venereology*. 2008 Nov 2008;22(11):1290-1301.
46. Meurer M, Folster-Holst R, Wozel G, et al. Pimecrolimus cream in the long-term management of atopic dermatitis in adults: a six-month study. *Dermatology*. 2002 2002;205(3):271-277.
47. Gollnick H, Kaufmann R, Stough D, et al. Pimecrolimus cream 1% in the long-term management of adult atopic dermatitis: prevention of flare progression. A randomized controlled trial. *British Journal of Dermatology*. 2008 May 2008;158(5):1083-1093.
48. Hoeger PH, Lee KH, Jautova J, et al. The treatment of facial atopic dermatitis in children who are intolerant of, or dependent on, topical corticosteroids: A randomized, controlled clinical trial. *British Journal of Dermatology*. February 2009;160(2):415-422.
49. Murrell DF, Calvieri S, Ortonne JP, et al. A randomized controlled trial of pimecrolimus cream 1% in adolescents and adults with head and neck atopic dermatitis and intolerant of, or dependent on, topical corticosteroids. *Br J Dermatol*. 2007 2007;157(5):954-959.
50. Leung DY, Hanifin JM, Pariser DM, et al. Effects of pimecrolimus cream 1% in the treatment of patients with atopic dermatitis who demonstrate a clinical insensitivity to topical corticosteroids: a randomized, multicentre vehicle-controlled trial. *British Journal of Dermatology*. Aug 2009;161(2):435-443.
51. Ho VC, Gupta A, Kaufmann R, et al. Safety and efficacy of nonsteroid pimecrolimus cream 1% in the treatment of atopic dermatitis in infants. *Journal of Pediatrics*. 2003 2003;142(2):155-162.
52. Eichenfield LF, Lucky AW, Boguniewicz M, et al. Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents.[see comment]. *Journal of the American Academy of Dermatology*. 2002 Apr 2002;46(4):495-504.
53. Kaufmann R, Bieber T, Helgesen AL, et al. Onset of pruritus relief with pimecrolimus cream 1% in adult patients with atopic dermatitis: a randomized trial. *Allergy*. 2006 2006;61(3):375-381.
54. Kaufmann R, Folster-Holst R, Hoger P, et al. Onset of action of pimecrolimus cream 1% in the treatment of atopic eczema in infants. *Journal of Allergy and Clinical Immunology*. 2004 2004;114(5):1183-1188.
55. Fowler J, Johnson A, Chen M, et al. Improvement in pruritus in children with atopic dermatitis using pimecrolimus cream 1%. *Cutis; cutaneous medicine for the practitioner*. 2007 2007;79(1):65-72.
56. Leo HL, Bender BG, Leung SB, et al. Effect of pimecrolimus cream 1% on skin condition and sleep disturbance in children with atopic dermatitis. *Journal of Allergy and Clinical Immunology*. 2004 2004;114(3):691-693.
57. Aschoff R, Schwanebeck U, Br, et al. Skin physiological parameters confirm the therapeutic efficacy of pimecrolimus cream 1% in patients with mild-to-moderate atopic dermatitis. *Experimental Dermatology*. Jan 2009;18(1):24-29.
58. Chen SL, Yan J, Wang FS. Two topical calcineurin inhibitors for the treatment of atopic dermatitis in pediatric patients: a meta-analysis of randomized clinical trials. *The Journal of dermatological treatment*. May 2010;21(3):144-156.
59. Paller A, Eichenfield LF, Leung DY, et al. A 12-week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients. *Journal of the American Academy of Dermatology*. Jan 2001;44(1 Suppl):S47-57.
60. Hanifin JM, Ling MR, Langley R, et al. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part I, efficacy. *Journal of the American Academy of Dermatology*. Jan 2001;44(1 Suppl):S28-38.
61. Chapman MS, Schachner LA, Breneman D, et al. Tacrolimus ointment 0.03% shows efficacy and safety in pediatric and adult patients with mild to moderate atopic dermatitis. *Journal of the American Academy of Dermatology*. Aug 2005;53(2 Suppl 2):S177-185.
62. Dou X, Liu L, Xie Z, et al. [The impact of tacrolimus ointment on health-related quality of life of Chinese adult and pediatric patients with atopic dermatitis]. *Journal of Clinical Dermatology*. 2006 2006;35(1):50-52.
63. Otsuki M, Kawashima M, Shibata Y, et al. [Efficacy and Safety of FK506 (Tacrolimus) Ointment in Children with Atopic Dermatitis-Phase III Double-blinded Comparison with Vehicle Ointment]. *Journal of Clinical Therapeutics and Medicines*. 2003;19(6):569-595.
64. Rahman MF, Rashid MM, Sikder AU, et al. Efficacy of topical tacrolimus in atopic dermatitis. *Journal of Pakistan Association of Dermatologists*. 2008; 18(2):84-92.
65. Granlund H, Remitz A, Kyllonen H, et al. Treatment of lichenified atopic eczema with tacrolimus ointment. *Acta Derm-Venereol*. 2001 Aug-Sep 2001;81(4):314-315.
66. Reitamo S, Van Leent EJ, Ho V, et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone acetate ointment in children with atopic dermatitis.[see comment][summary for patients in Curr Allergy Asthma Rep. 2002 Jul;2(4):273-4; PMID: 12044259]. *Journal of Allergy & Clinical Immunology*. 2002 Mar 2002;109(3):539-546.
67. Reitamo S, Harper J, Bos JD, et al. 0.03% Tacrolimus ointment applied once or twice daily is more efficacious than 1% hydrocortisone acetate in children with moderate to severe atopic dermatitis: results of a randomized double-blind controlled trial.[see comment]. *British Journal of Dermatology*. 2004 Mar 2004;150(3):554-562.
68. Cury Martins J, Martins C, Aoki V, et al. Topical tacrolimus for atopic dermatitis. *The Cochrane database of systematic reviews*. 2015;7:Cd009864.

69. Doss N, Reitamo S, Dubertret L, et al. Superiority of tacrolimus 0.1% ointment compared with fluticasone 0.005% in adults with moderate to severe atopic dermatitis of the face: results from a randomized, double-blind trial. *British Journal of Dermatology*. Aug 2009;161(2):427-434.
70. Paller AS, Lebwohl M, Fleischer AB, Jr., et al. Tacrolimus ointment is more effective than pimecrolimus cream with a similar safety profile in the treatment of atopic dermatitis: results from 3 randomized, comparative studies. *Journal of the American Academy of Dermatology*. May 2005;52(5):810-822.
71. Kempers S, Boguniewicz M, Carter E, et al. A randomized investigator-blinded study comparing pimecrolimus cream 1% with tacrolimus ointment 0.03% in the treatment of pediatric patients with moderate atopic dermatitis. *Journal of the American Academy of Dermatology*. Oct 2004;51(4):515-525.
72. Draelos Z, Nayak A, Pariser D, et al. Pharmacokinetics of topical calcineurin inhibitors in adult atopic dermatitis: a randomized, investigator-blind comparison. *Journal of the American Academy of Dermatology*. Oct 2005;53(4):602-609.
73. Peserico A, Stadtler G, Sebastian M, et al. Reduction of relapses of atopic dermatitis with methylprednisolone aceponate cream twice weekly in addition to maintenance treatment with emollient: a multicentre, randomized, double-blind, controlled study. *Br J Dermatol*. Apr 2008;158(4):801-807.
74. Hanifin J, Gupta AK, Rajagopalan R. Intermittent dosing of fluticasone propionate cream for reducing the risk of relapse in atopic dermatitis patients. *British Journal of Dermatology*. 2002 2002;147(3):528-537.
75. Berth-Jones J, Damstra RJ, Golsch S, et al. Twice weekly fluticasone propionate added to emollient maintenance treatment to reduce risk of relapse in atopic dermatitis: randomised, double blind, parallel group study. *BMJ (Clinical research ed.)*. Jun 21 2003;326(7403):1367.
76. Glazenburg EJ, Wolkerstorfer A, Gerretsen AL, et al. Efficacy and safety of fluticasone propionate 0.005% ointment in the long-term maintenance treatment of children with atopic dermatitis: differences between boys and girls? *Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology*. 2009;20(1):59-66.
77. Breneman D, Fleischer AB, Abramovits W, et al. Intermittent therapy for flare prevention and long-term disease control in stabilized atopic dermatitis: a randomized comparison of 3-times-weekly applications of tacrolimus ointment versus vehicle. *Journal of the American Academy of Dermatology*. 2008 2008;58(6):990-999.
78. Thaci D, Reitamo S, Gonzalez Ensenat MA, et al. Proactive disease management with 0.03% tacrolimus ointment for children with atopic dermatitis: results of a randomized, multicentre, comparative study. *British Journal of Dermatology*. 2008 Dec 2008;159(6):1348-1356.
79. Wollenberg A, Reitamo S, Atzori F, et al. Proactive treatment of atopic dermatitis in adults with 0.1% tacrolimus ointment.[republished in Allergy. 2008 Jul;63(7):742-50; PMID: 18592619]. *Allergy*. 2008 Jun 2008;63(6):742-750.
80. Takeuchi. A Randomized, Open-Label, Multicenter Trial of Topical Tacrolimus for the Treatment of Pruritus in Patients with Atopic Dermatitis. *Annals of Dermatology*. 2012.
81. Bangert. Clinical and cytological effects of pimecrolimus cream 1% after resolution of active atopic dermatitis lesions by topical corticosteroids: A randomised controlled trial. *Dermatology*. 2011.
82. Munro CS, Levell NJ, Shuster S, et al. Maintenance treatment with cyclosporin in atopic eczema. *Br J Dermatol*. Mar 1994;130(3):376-380.
83. van Joost T, Heule F, Korstanje M, et al. Cyclosporin in atopic dermatitis: a multicentre placebo-controlled study. *Br J Dermatol*. May 1994;130(5):634-640.
84. Sowden JM, Berth-Jones J, Ross JS, et al. Double-blind, controlled, crossover study of cyclosporin in adults with severe refractory atopic dermatitis. *Lancet (London, England)*. Jul 20 1991;338(8760):137-140.
85. Wahlgren CF, Scheynius A, Hagermark O. Antipruritic effect of oral cyclosporin A in atopic dermatitis. *Acta Derm-Venerol*. 1990;70(4):323-329.
86. Schmitt J, Schmitt N, Meurer M. Cyclosporin in the treatment of patients with atopic eczema - a systematic review and meta-analysis. *Journal of the European Academy of Dermatology and Venereology : JEADV*. May 2007;21(5):606-619.
87. Meggitt SJ, Gray JC, Reynolds NJ. Azathioprine dosed by thiopurine methyltransferase activity for moderate-to-severe atopic eczema: a double-blind, randomised controlled trial. *Lancet (London, England)*. Mar 11 2006;367(9513):839-846.
88. Berth-Jones J, Takwale A, Tan E, et al. Azathioprine in severe adult atopic dermatitis: a double-blind, placebo-controlled, crossover trial. *British Journal of Dermatology*. 2002 Aug 2002;147(2):324-330.
89. Schram ME, Borgonjen RJ, Bik CM, et al. Off-label use of azathioprine in dermatology: a systematic review. *Arch Dermatol*. Apr 2011;147(4):474-488.
90. Jekler J, Larko O. UVB phototherapy of atopic dermatitis. *Br J Dermatol*. Dec 1988;119(6):697-705.
91. Reynolds NJ, Franklin V, Gray JC, et al. Narrow-band ultraviolet B and broad-band ultraviolet A phototherapy in adult atopic eczema: a randomised controlled trial. *Lancet (London, England)*. 2001 Jun 23 2001;357(9273):2012-2016.
92. Dogra S, Mahajan R. Phototherapy for atopic dermatitis. *Indian journal of dermatology, venereology and leprology*. Jan-Feb 2015;81(1):10-15.
93. Gambichler T, Breuckmann F, Boms S, et al. Narrowband UVB phototherapy in skin conditions beyond psoriasis. *Journal of the American Academy of Dermatology*. Apr 2005;52(4):660-670.

94. Patrizi A, Capitanio B, Neri I, et al. A double-blind, randomized, vehicle-controlled clinical study to evaluate the efficacy and safety of MAS063DP (ATOPICLAIR) in the management of atopic dermatitis in paediatric patients. *Pediatric Allergy & Immunology*. 2008 Nov 2008;19(7):619-625.
95. Boguniewicz M, Zeichner JA, Eichenfield LF, et al. MAS063DP is effective monotherapy for mild to moderate atopic dermatitis in infants and children: a multicenter, randomized, vehicle-controlled study. *The Journal of pediatrics*. 2008 2008;152(6):854-859.
96. Abramovits W, Boguniewicz M, Adult Atopiclair Study G. A multicenter, randomized, vehicle-controlled clinical study to examine the efficacy and safety of MAS063DP (Atopiclair) in the management of mild to moderate atopic dermatitis in adults. *Journal of drugs in dermatology : JDD*. 2006 2006;5(3):236-244.
97. Belloni G, Pinelli S, Veraldi S. A randomised, double-blind, vehicle-controlled study to evaluate the efficacy and safety of MAS063D (Atopiclair) in the treatment of mild to moderate atopic dermatitis. *European Journal of Dermatology*. 2005 Jan-Feb 2005;15(1):31-36.
98. Miller DW, Koch SB, Yentzer BA, et al. An over-the-counter moisturizer is as clinically effective as, and more cost-effective than, prescription barrier creams in the treatment of children with mild-to-moderate atopic dermatitis: a randomized, controlled trial. *J Drugs Dermatol*. May 2011;10(5):531-537.
99. Span L, Molier L, Coenraads PJ, et al. Intensive daycare for young adults with atopic eczema. *Nederlands Tijdschrift voor Dermatologie & Venereologie*. 2001 2001;11:279-283.
100. Shaw M, Morrell DS, Goldsmith LA. A study of targeted enhanced patient care for pediatric atopic dermatitis (STEP PAD). *Pediatric Dermatology*. 2008 2008;25(1):19-24.
101. Staab D, Diepgen TL, Fartasch M, et al. Age related, structured educational programmes for the management of atopic dermatitis in children and adolescents: multicentre, randomised controlled trial.[see comment]. *BMJ (Clinical research ed.)*. 2006 Apr 22 2006;332(7547):933-938.
102. Staab D, von Rueden U, Kehrt R, et al. Evaluation of a parental training program for the management of childhood atopic dermatitis. *Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology*. 2002 2002;13(2):84-90.
103. Grillo M, Gassner L, Marshman G, et al. Pediatric atopic eczema: the impact of an educational intervention. *Pediatric Dermatology*. 2006 2006;23(5):428-436.
104. Futamura M, MI, Hayashi K., Ohya Y., Ito K. Effects of a short-term parental education program on childhood atopic dermatitis: A randomized controlled trial. *Pediatric Dermatology*. 2013:438 - 443.
105. Kardorff B, Schnelle-Parker G, Kardorff M, et al. Successful reduction of the SCORAD score by a short-time teaching method using a simplified skin model in children with atopic eczema in a 6-week comparison. *Journal der Deutschen Dermatologischen Gesellschaft*. 2003 2003;1(6):451-456.
106. Ersser SJ, Cowdell F, Latter S, et al. Psychological and educational interventions for atopic eczema in children. *The Cochrane database of systematic reviews*. 2014;1:CD004054.
107. Bleehen SS, Chu AC, Hamann I, et al. Fluticasone propionate 0.05% cream in the treatment of atopic eczema: A multicentre study comparing once-daily treatment and once-daily vehicle cream application versus twice-daily treatment. *British Journal of Dermatology*. 1995;133 (4):592-597.
108. Koopmans B, Lasthein AB, Mork NJ, et al. Multicentre randomized double-blind study of Locoid Lipocream fatty cream twice daily versus Locoid Lipocream once daily and Locobase once daily. *Journal of Dermatological Treatment*. 1995;6(2):103-106.
109. Green C, Colquitt JL, Kirby J, et al. Topical corticosteroids for atopic eczema: clinical and cost effectiveness of once-daily vs. more frequent use. *Br J Dermatol*. Jan 2005;152(1):130-141.
110. Hung SH, Lin YT, Chu CY, et al. Staphylococcus colonization in atopic dermatitis treated with fluticasone or tacrolimus with or without antibiotics. *Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology*. 2007 2007;98(1):51-56.
111. Gong JQ, Lin L, Lin T, et al. Skin colonization by Staphylococcus aureus in patients with eczema and atopic dermatitis and relevant combined topical therapy: a double-blind multicentre randomized controlled trial. *British Journal of Dermatology*. 2006 Oct 2006;155(4):680-687.
112. Ravenscroft JC, Layton AM, Eady EA, et al. Short-term effects of topical fusidic acid or mupirocin on the prevalence of fusidic acid resistant (FusR) Staphylococcus aureus in atopic eczema. *Br J Dermatol*. May 2003;148(5):1010-1017.
113. Canpolat F, Erkocoglu, M., Tezer, H., Kocabas, C. N., Kandi, B. Hydrocortisone acetate alone or combined with mupirocin for atopic dermatitis in infants under two years of age - a randomized double blind pilot trial. *European Review for Medical & Pharmacological Sciences*. 2012.
114. Schuttelaar ML, Coenraads PJ. A randomized, double-blind study to assess the efficacy of addition of tetracycline to triamcinolone acetonide in the treatment of moderate to severe atopic dermatitis. *Journal of the European Academy of Dermatology & Venereology*. 2008 Sep 2008;22(9):1076-1082.
115. Bath-Hextall FJ, Birnie AJ, Ravenscroft JC, et al. Interventions to reduce Staphylococcus aureus in the management of atopic eczema: an updated Cochrane review. *Br J Dermatol*. 2010;163(1):12-26.
116. Rosenfeldt V, Benfeldt E, Nielsen SD, et al. Effect of probiotic Lactobacillus strains in children with atopic dermatitis. *The Journal of allergy and clinical immunology*. 2003 2003;111(2):389-395.
117. Sistek D, Kelly R, Wickens K, et al. Is the effect of probiotics on atopic dermatitis confined to food sensitized children? *Clinical & Experimental Allergy*. 2006 May 2006;36(5):629-633.

118. Cukrowska B, Ceregra A, Rosiak I, et al. The influence of probiotic *Lactobacillus casei* and *paracasei* strains on clinical status of atopic eczema in children with food allergy on cow's milk proteins. [Polish]. *Pediatrica Wspolczesna*. 10(2)(pp 67-70), 2008. Date of Publication: 2008.
119. Yesilova. Effect of Probiotics on the Treatment of Children with Atopic Dermatitis. *Annals of Dermatology*. 2012.
120. Iemoli E, Trabattoni, D., Parisotto, S., Borgonovo, L., Toscano, M., Rizzardini, G., Clerici, M., Ricci, E., Fusi, A., De Vecchi, E., Piconi, S., Drago, L., Iemoli, Enrico, Trabattoni, Daria, Parisotto, Serena, Borgonovo, Linda, Toscano, Marco, Rizzardini, Giuliano, Clerici, Mario, Ricci, Elena, Fusi, Alessandra, De Vecchi, Elena, Piconi, Stefania, Drago, Lorenzo. Probiotics reduce gut microbial translocation and improve adult atopic dermatitis. *Journal of Clinical Gastroenterology*. 2012.
121. Nermes M, Kantele JM, Atosuo TJ, et al. Interaction of orally administered *Lactobacillus rhamnosus* GG with skin and gut microbiota and humoral immunity in infants with atopic dermatitis. *Clinical and Experimental Allergy*. March;41 (3):370-377.
122. Grüber C, Wendt M, Sulser C, et al. Randomized, placebo-controlled trial of *Lactobacillus rhamnosus* GG as treatment of atopic dermatitis in infancy. *Allergy*. 2007 2007;62(11):1270-1276.
123. Brouwer ML, Wolt-Plompen SA, Dubois AE, et al. No effects of probiotics on atopic dermatitis in infancy: a randomized placebo-controlled trial. *Clinical & Experimental Allergy*. 2006 Jul 2006;36(7):899-906.
124. Folster-Holst R, Muller F, Schnopp N, et al. Prospective, randomized controlled trial on *Lactobacillus rhamnosus* in infants with moderate to severe atopic dermatitis. *British Journal of Dermatology*. 2006 2006;155(6):1256-1261.
125. Viljanen M, Savilahti E, Haahtela T, et al. Probiotics in the treatment of atopic eczema/dermatitis syndrome in infants: a double-blind placebo-controlled trial. *Allergy*. 2005 2005;60(4):494-500.
126. Moroi M, Uchi S, Nakamura K, et al. Beneficial effect of a diet containing heat-killed *Lactobacillus paracasei* K71 on adult type atopic dermatitis. *Journal of Dermatology*. February;38 (2):131-139.
127. Gobel R, Larsen N, Molgaard C, et al. Probiotics to young children with atopic dermatitis: A randomized placebo-controlled trial. *International Journal of Probiotics and Prebiotics*. May 2010;5 (2):53-59.
128. Woo SI, Kim JY, Lee YJ, et al. Effect of *Lactobacillus sakei* supplementation in children with atopic eczema-dermatitis syndrome. *Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology*. 2010(4):343-348.
<http://www.mrw.interscience.wiley.com/cochrane/clcentral/articles/516/CN-00742516/frame.html>.
129. Weston S, Halbert A, Richmond P, et al. Effects of probiotics on atopic dermatitis: a randomised controlled trial. *Arch Dis Child*. Sep 2005;90(9):892-897.
130. Torii S, Torii A, Itoh K, et al. Effects of oral administration of *Lactobacillus acidophilus* I-92 on the symptoms and serum markers of atopic dermatitis in children. *International Archives of Allergy and Immunology*. February;154 (3):236-245.
131. Drago L, Iemoli E, Rodighiero V, et al. Effects of *Lactobacillus salivarius* LS01 (DSM 22775) treatment on adult atopic dermatitis: A randomized placebo-controlled study. *International Journal of Immunopathology and Pharmacology*. October-December 2011;24 (4):1037-1048.
132. Gore. Treatment and secondary prevention effects of the probiotics *Lactobacillus paracasei* or *Bifidobacterium lactis* on early infant eczema: randomized controlled trial with follow-up until age 3 years. *Clinical & Experimental Allergy*. 2012.
133. Han Y, Kim, B., Ban, J., Lee, J., Kim, B. J., Choi, B. S., Hwang, S., Ahn, K., Kim, J., Han, Youngshin, Kim, Bongjoon, Ban, Jeongsook, Lee, Jeongok, Kim, Beom Joon, Choi, Byung Sun, Hwang, Sehee, Ahn, Kangmo, Kim, Jihyun. A randomized trial of *Lactobacillus plantarum* CJLP133 for the treatment of atopic dermatitis. *Pediatric Allergy & Immunology*. 2012.
134. Isolauri E, Arvola T, Sutas Y, et al. Probiotics in the management of atopic eczema. *Clinical & Experimental Allergy*. 2000 Nov 2000;30(11):1604-1610.
135. Taniuchi S, Hattori K, Yamamoto A, et al. Administration of *Bifidobacterium* to infants with atopic dermatitis: changes in fecal microflora and clinical symptoms. *Journal of Applied Research*. 2005 2005;5(2):387-396.
136. Boyle RJ, Bath-Hextall FJ, Leonardi-Bee J, et al. Probiotics for the treatment of eczema: a systematic review. *Clin Exp Allergy*. 2009;39(8):1117-1127.
137. Takwale A, Tan E, Agarwal S, et al. Efficacy and tolerability of borage oil in adults and children with atopic eczema: randomised, double blind, placebo controlled, parallel group trial. *BMJ (Clinical research ed.)*. 2003 2003;327(7428):1385.
138. Bahmer FA, Schäfer J. [Treatment of atopic dermatitis with borage seed oil (Glandol)--a time series analytic study]. *Kinderärztliche Praxis*. 1992;60(7):199-202.
139. Borrek S, Hildebrandt A, Forster J. Gamma-linolenic-acid-rich borage seed oil capsules in children with atopic dermatitis. A placebo-controlled double-blind study. [German]. *Klinische Padiatrie*. 1997;209 (3):100-104.
140. Buslau M, Thaci D. Atopic dermatitis: Borage oil for systemic therapy. [German]. *Zeitschrift für Dermatologie*. 1996;182 (3):131-132+134-136.
141. Henz BM, Jablonska S, van de Kerkhof PC, et al. Double-blind, multicentre analysis of the efficacy of borage oil in patients with atopic eczema. *British Journal of Dermatology*. 1999;140(4):685-688.
142. Valsecchi R, Di Landro A, Pansera B, et al. Gammalinolenic acid in the treatment of atopic dermatitis [1]. *Journal of the European Academy of Dermatology and Venereology*. 1996;7 (1):77-79.

143. Senapati S, Banerjee S, Gangopadhyay DN. Evening primrose oil is effective in atopic dermatitis: a randomized placebo-controlled trial. *Indian Journal of Dermatology, Venereology & Leprology*. 2008 Sep-Oct 2008;74(5):447-452.
144. Bamford JT, Ray S, Musekiwa A, et al. Oral evening primrose oil and borage oil for eczema. 2013.
145. Berth-Jones J, Graham-Brown RA. Placebo-controlled trial of essential fatty acid supplementation in atopic dermatitis *Lancet* 1993 Aug 28;342(8870):564. *Lancet (London, England)*. 1993;341(8860):1557-1560.
146. Biagi PL, Bordon A, Hrelia S, et al. The effect of gamma-linolenic acid on clinical status, red cell fatty acid composition and membrane microviscosity in infants with atopic dermatitis. *Drugs under Experimental and Clinical Research*. 1994;20 (2):77-84.
147. Bordon A, Biagi PL, Masi M, et al. Evening primrose oil (Efamol) in the treatment of children with atopic eczema. *Drugs under Experimental and Clinical Research*. 1988;14 (4):291-297.
148. Hederos CA, Berg A. Epogam evening primrose oil treatment in atopic dermatitis and asthma. *Archives of Disease in Childhood*. 1996;75 (6):494-497.
149. Humphreys F, Symons JA, Brown HK, et al. The effects of gamma-linolenic acid on adult atopic eczema and premenstrual exacerbation of eczema. *European Journal of Dermatology*. 1994;4 (8):598-603.
150. Mayser P, Mayer K, Mahlouljian M, et al. A double-blind, randomized, placebo-controlled trial of n-3 versus n-6 fatty acid-based lipid infusion in atopic dermatitis. *Jpen: Journal of Parenteral & Enteral Nutrition*. 2002 May-Jun 2002;26(3):151-158.
151. Bjorneboe A, Soyland E, Bjorneboe GE, et al. Effect of n-3 fatty acid supplement to patients with atopic dermatitis. *Journal of Internal Medicine Supplement*. 1989;731:233-236.
152. Gimenez-Arnau A. Effects of linoleic acid supplements on atopic dermatitis. *Advances in Experimental Medicine and Biology*. 1997;433:285-289.
153. Soyland E, Funk J, Rajka G, et al. Dietary supplementation with very long-chain n-3 fatty acids in patients with atopic dermatitis. A double-blind, multicentre study. *British Journal of Dermatology*. 1994;130 (6):757-764.
154. Koch C, Dolle S, Metzger M, et al. Docosahexaenoic acid (DHA) supplementation in atopic eczema: a randomized, double-blind, controlled trial. *Br J Dermatol*. Apr 2008;158(4):786-792.
155. Callaway J, Schwab U, Harvima I, et al. Efficacy of dietary hempseed oil in patients with atopic dermatitis. *Journal of Dermatological Treatment*. 2005 Apr 2005;16(2):87-94.
156. Lovell CR, Burton JL, Horrobin DF. Treatment of atopic eczema with evening primrose oil. *Lancet (London, England)*. 1981;1(8214):278.
157. Schalin-Karrila M, Mattila L, Jansen CT, et al. Evening primrose oil in the treatment of atopic eczema: Effect on clinical status, plasma phospholipid fatty acids and circulating blood prostaglandins. *British Journal of Dermatology*. 1987;117 (1):11-19.
158. Wright S, Burton JL. Oral evening-primrose-seed oil improves atopic eczema. *Lancet (London, England)*. 1982;2 (8308):1120-1122.
159. Bamford JT, Ray S, Musekiwa A, et al. Oral evening primrose oil and borage oil for eczema. *Cochrane Database Syst Rev*. 2013;4:CD004416.
160. Foelster Holst R, Reitamo S, Yankova R, et al. The novel protease inhibitor SRD441 ointment is not effective in the treatment of adult subjects with atopic dermatitis: results of a randomized, vehicle-controlled study. *Allergy*. Dec 2010;65(12):1594-1599.
161. Tripodi S, Di Rienzo Businco A, Panetta V, et al. Lack of efficacy of topical furfuryl palmitate in pediatric atopic dermatitis: A randomized double-blind study. *Journal of Investigational Allergology and Clinical Immunology*. 2009;19(3):204-209.
162. Thomas KS, Dean T, O'Leary C, et al. A randomised controlled trial of ion-exchange water softeners for the treatment of eczema in children. *PLoS medicine*. 2011;8(2):e1000395.
163. Griffiths CE, Van Leent EJ, Gilbert M, et al. Randomized comparison of the type 4 phosphodiesterase inhibitor cipamfylline cream, cream vehicle and hydrocortisone 17-butyrate cream for the treatment of atopic dermatitis. *British Journal of Dermatology*. 2002 Aug 2002;147(2):299-307.
164. Arkwright PD, David TJ. Intradermal administration of a killed *Mycobacterium vaccae* suspension (SRL 172) is associated with improvement in atopic dermatitis in children with moderate-to-severe disease. *The Journal of allergy and clinical immunology*. 2001 2001;107(3):531-534.
165. Arkwright PD, David TJ. Effect of *Mycobacterium vaccae* on atopic dermatitis in children of different ages. *Br J Dermatol*. Nov 2003;149(5):1029-1034.
166. Berth-Jones J, Arkwright PD, Marasovic D, et al. Killed *Mycobacterium vaccae* suspension in children with moderate-to-severe atopic dermatitis: a randomized, double-blind, placebo-controlled trial. *Clin Exp Allergy*. Sep 2006;36(9):1115-1121.
167. Brothers S, Asher MI, Jaksic M, et al. Effect of a *Mycobacterium vaccae* derivative on paediatric atopic dermatitis: A randomized, controlled trial. *Clinical and Experimental Dermatology*. October 2009;34(7):770-775.
168. Kantor I, Milbauer J, Posner M, et al. Efficacy and safety of emollients as adjunctive agents in topical corticosteroid therapy for atopic dermatitis. *Today's Therapeutic Trends*. 1993;11 (3):157-166.
169. Hanifin JM, Hebert AA, Mays SR, et al. Effects of a low-potency corticosteroid lotion plus a moisturizing regimen in the treatment of atopic dermatitis. *Current Therapeutic Research - Clinical and Experimental*. 1998;59 (4):227-233.

170. Wilhelm KP, Scholermann A. Efficacy and tolerability of a topical preparation containing 10% urea in patients with atopic dermatitis: <ORIGINAL> WIRKSAMKEIT UND VERTRAGLICHKEIT EINER TOPISCHEN ZUBEREITUNG MIT 10% UREA (LACERAN (R)) SALBE 10% UREA) BEI NEURODERMITIS. *Aktuelle Dermatologie*. 1998;24(1-2):26-30.
171. Larregue M, Devaux J, Audebert C, et al. A double-blind controlled study on the efficacy and tolerability of 6% ammonium lactate cream in children with atopic dermatitis. [French]. *Nouvelles Dermatologiques*. 1996;15(10):720-721.
172. Draelos ZD. A clinical evaluation of the comparable efficacy of hyaluronic acid-based foam and ceramide-containing emulsion cream in the treatment of mild-to-moderate atopic dermatitis. *Journal of Cosmetic Dermatology*. September 2011;10(3):185-188.
173. Draelos ZD, Draelos ZD. An evaluation of prescription device moisturizers. *Journal of Cosmetic Dermatology*. Mar 2009;8(1):40-43.
174. Wiren K, Nohlgard C, Nyberg F, et al. Treatment with a barrier-strengthening moisturizing cream delays relapse of atopic dermatitis: A prospective and randomized controlled clinical trial. *Journal of the European Academy of Dermatology and Venereology*. November 2009;23(11):1267-1272.
175. Berardesca E, Barbareschi M, Veraldi S, et al. Evaluation of efficacy of a skin lipid mixture in patients with irritant contact dermatitis, allergic contact dermatitis or atopic dermatitis: a multicenter study. *Contact Dermatitis*. 2001 Nov 2001;45(5):280-285.
176. Sugarman JL, Parish LC, Sugarman JL, et al. Efficacy of a lipid-based barrier repair formulation in moderate-to-severe pediatric atopic dermatitis. *Journal of Drugs in Dermatology: JDD*. Dec 2009;8(12):1106-1111.
177. Miller. An over the counter moisturizer is as clinically effective as, and more cost-effective than, prescription barrier creams in the treatment of children with mild to moderate atopic dermatitis: A randomised, controlled trial. *Journal of Drugs in Dermatology*. 2011.
178. Simpson. A New Body Moisturizer Increases Skin Hydration and Improves Atopic Dermatitis Symptoms Among Children and Adults. *Journal of Drugs in Dermatology*. 2011.
179. Grimalt R, Mengeaud V, Cambazard F, et al. The steroid-sparing effect of an emollient therapy in infants with atopic dermatitis: a randomized controlled study. *Dermatology*. 2007 2007;214(1):61-67.
180. Giordano-Labadie F, Cambazard F, Guillet G, et al. Evaluation of a new moisturizer (Exomega milk) in children with atopic dermatitis. *Journal of Dermatological Treatment*. 2006 2006;17(2):78-81.
181. Bissonnette R, Maari C, Provost N, et al. A double-blind study of tolerance and efficacy of a new urea-containing moisturizer in patients with atopic dermatitis. *Journal of Cosmetic Dermatology*. 2010(1):16-21. <http://www.mrw.interscience.wiley.com/cochrane/clcentral/articles/896/CN-00751896/frame.html>.
182. Loden M, Andersson AC, Anderson C, et al. A double-blind study comparing the effect of glycerin and urea on dry, eczematous skin in atopic patients. *Acta Dermato-Venereologica*. 2002 2002;82(1):45-47.
183. Amichai B, Grunwald MH. A randomized, double-blind, placebo-controlled study to evaluate the efficacy in AD of liquid soap containing 12% ammonium lactate + 20% urea. *Clinical & Experimental Dermatology*. 2009;34(8):e602-604.
184. Msika P, De Belilovsky C, Piccardi N, et al. New Emollient with Topical Corticosteroid-Sparing Effect in Treatment of Childhood Atopic Dermatitis: SCORAD and Quality of Life Improvement. *Pediatric Dermatology*. 2008 Nov-Dec 2008;25(6):606-612.
185. De Belilovsky C, Roo-Rodriguez E, Baudouin C, et al. Natural peroxisome proliferator-activated receptor-alpha agonist cream demonstrates similar therapeutic response to topical steroids in atopic dermatitis. *Journal of Dermatological Treatment*. December 2011;22(6):359-365.
186. Loden M, Andersson AC, Andersson C, et al. Instrumental and dermatologist evaluation of the effect of glycerine and urea on dry skin in atopic dermatitis. *Skin Research and Technology*. 2001 2001;7(4):209-213.
187. Shibata R, Kimura M, Takahashi H, et al. Clinical effects of kestose, a prebiotic oligosaccharide, on the treatment of atopic dermatitis in infants. *Clinical & Experimental Allergy*. Sep 2009;39(9):1397-1403.
188. Ghanei. Effectiveness of prebiotic in atopic dermatitis reduction in 7 to 24 months old children living in Isfahan. *Journal of Isfahan Medical School*. 2011.
189. van der Aa LB, Heymans HS, van Aalderen WM, et al. Effect of a new synbiotic mixture on atopic dermatitis in infants: a randomized-controlled trial. *Clinical & Experimental Allergy*. May 2010;40(5):795-804.
190. Passeron T, Lacour JP, Fontas E, et al. Prebiotics and synbiotics: two promising approaches for the treatment of atopic dermatitis in children above 2 years. *Allergy*. 2006 2006;61(4):431-437.
191. Gerasimov SV, Vasjuta VV, Myhovich OO, et al. Probiotic supplement reduces atopic dermatitis in preschool children: a randomized, double-blind, placebo-controlled, clinical trial. *American Journal of Clinical Dermatology*. 2010;11(5):351-361.
192. Hattori K, Yamamoto A, Sasai M, et al. [Effects of administration of bifidobacteria on fecal microflora and clinical symptoms in infants with atopic dermatitis]. [Japanese]. *Arerugi - Japanese Journal of Allergology*. 2003 Jan 2003;52(1):20-30.
193. Murosaki S, Yamamoto Y, Yotsumoto H, et al. Effects of intake of syrup supplemented with nigerooligosaccharides and heat-killed *Lactobacillus plantarum* L-137 on skin symptom and immune function in patients with atopic dermatitis. [Japanese]. *Japanese Pharmacology and Therapeutics*. 34(10)(pp 1087-1096), 2006. Date of Publication: 2006.

194. Farid R, Ahanchian H, Jabbari F, et al. Effect of a new synbiotic mixture on atopic dermatitis in children: A randomized-controlled trial. *Iranian Journal of Pediatrics*. 2011;21 (2):225-230.
195. Shafiei. Synbiotics could not Reduce the Scoring of Childhood Atopic Dermatitis (SCORAD): A Randomised Double Blind Placebo-Controlled Trial. *Iranian Journal of Allergy, Asthma and Immunology*. 2011.
196. Wu. Lactobacillus salivarius plus fructo-oligosaccharide is superior to fructo-oligosaccharide alone for treating children with moderate to severe atopic dermatitis: a double-blind, randomized, clinical trial of efficacy and safety. *British Journal of Dermatology*. 2012.
197. Vita D, Passalacqua G, Di Pasquale G, et al. Ass's milk in children with atopic dermatitis and cow's milk allergy: crossover comparison with goat's milk. *Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology*. 2007 2007;18(7):594-598.
198. Leung TF, Ma KC, Cheung LT, et al. A randomized, single-blind and crossover study of an amino acid-based milk formula in treating young children with atopic dermatitis. *Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology*. 2004 2004;15(6):558-561.
199. Jin. Partially hydrolyzed cow's milk formula has a therapeutic effect on the infants with mild to moderate atopic dermatitis: a randomized, double-blind study. *Pediatric Allergy & Immunology*. 2011.
200. Koller DY, Halmerbauer G, Böck A, et al. Action of a silk fabric treated with AEGIS in children with atopic dermatitis: a 3-month trial. *Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology*. 2007 2007;18(4):335-338.
201. Stinco G, Piccirillo F, Valent F. A randomized double-blind study to investigate the clinical efficacy of adding a non-migrating antimicrobial to a special silk fabric in the treatment of atopic dermatitis. *Dermatology*. 2008 2008;217(3):191-195.
202. Fontanini C, Bi, Monasta L., Longo G. DermaSilk in long-term control of infantile atopic dermatitis: A double blind randomized controlled trial. *Giornale Italiano di Dermatologia e Venereologia*. 2013:293 - 297.
203. Ozawa M, Numata I, Watabe A, et al. Effect of underwear made from MEDIELE on skin barrier function of atopic dermatitis patients in winter season. [Japanese]. *Skin Research*. 7(4)(pp 475-481), 2008. Date of Publication: August 2008.
204. Yokoyama Y, Kimata H, Mitarai S, et al. Ethylene vinyl alcohol (EVOH) fiber compared to cotton underwear in the treatment of childhood atopic dermatitis: A double-blind randomized study. *Indian Pediatrics*. July 2009;46(7):611-614.
205. Gauger A, Fischer S, Mempel M, et al. Efficacy and functionality of silver-coated textiles in patients with atopic eczema. *Journal of the European Academy of Dermatology and Venereology : JEADV*. May 2006;20(5):534-541.
206. Juenger M, Ladwig A, Staecker S, et al. Efficacy and safety of silver textile in the treatment of atopic dermatitis (AD). *Current medical research and opinion*. 2006 2006;22(4):739-750.
207. Kim B, Kim C. Effect of mattress and pillow encasings on children with atopic dermatitis. *Journal of Allergy & Clinical Immunology*. 2005;115(2 Suppl):S101-S101.
208. Moore E, Williams A, Manias E, et al. Nurse-led clinics reduce severity of childhood atopic eczema: a review of the literature. *Br J Dermatol*. 2006;155(6):1242-1248.
209. Schuttelaar ML, Vermeulen KM, Drukker N, et al. A randomized controlled trial in children with eczema: nurse practitioner vs. dermatologist. *Br J Dermatol*. 2010 (1):162-170.
<http://www.mrw.interscience.wiley.com/cochrane/clcentral/articles/334/CN-00742334/frame.html>.
210. Blessmann Weber M, De Tarso Da Luz Fontes Neto P, Prati C, et al. Improvement of pruritus and quality of life of children with atopic dermatitis and their families after joining support groups. *Journal of the European Academy of Dermatology and Venereology*. 22(8)(pp 992-997), 2008. Date of Publication: August 2008.
211. Van Os-Medendorp H, Koffijberg H, Eland-De Kok PCM, et al. E-health in caring for patients with atopic dermatitis: A randomized controlled cost-effectiveness study of internet-guided monitoring and online self-management training. *British Journal of Dermatology*. May 2012;166 (5):1060-1068.
212. Schut C. WU, Tews N., Gieler U., Deinzer R., Kupfer J. Psychophysiological effects of stress management in patients with atopic dermatitis: A randomized controlled trial. *Acta Dermato-Venereologica*. 2013.
213. Byremo G, Rød G, Carlsen KH. Effect of climatic change in children with atopic eczema. *Allergy*. 2006 2006;61(12):1403-1410.
214. Ricci G, Patrizi A, Specchia F, et al. Effect of house dust mite avoidance measures in children with atopic dermatitis. *British Journal of Dermatology*. 2000;143(2):379-384.
215. Gutgesell C, Heise S, Seubert S, et al. Double-blind placebo-controlled house dust mite control measures in adult patients with dermatitis. *British Journal of Dermatology*. 2001;145(1):70-74.
216. Oosting AJ, de Bruin-Weller MS, Terreehorst I, et al. Effect of mattress encasings on atopic dermatitis outcome measures in a double-blind, placebo-controlled study: the Dutch mite avoidance study. *Journal of Allergy & Clinical Immunology*. 2002;110(3):500-506.
217. Sagransky MJ, Yentzer BA, Williams LL, et al. A randomized controlled pilot study of the effects of an extra office visit on adherence and outcomes in atopic dermatitis. *Archives of Dermatology*. 2010;146(12):1428-1430.
218. Glover MT, Atherton DJ. A double-blind controlled trial of hyposensitization to *Dermatophagoides pteronyssinus* in children with atopic eczema. *Clinical and Experimental Allergy*. 1992;22 (4):440-446.
219. Galli E, Chini L, Nardi S, et al. Use of a specific oral hyposensitization therapy to *Dermatophagoides pteronyssinus* in children with atopic dermatitis. *Allergologia et immunopathologia*. 1994;22(1):18-22.

220. Wen T, Wang E, Shen S, et al. Allergenic potency of SMU-Df extract in comparison with VUS-Df extract; and diagnosis and immunotherapy for atopic dermatitis and rhinitis with SMU-Df extract in China. *Arbeiten aus dem Paul-Ehrlich-Institut (Bundesamt für Sera und Impfstoffe) zu Frankfurt a.M.* 1992;(85):217-227.
221. Diepgen TL, Salzer B, Tepe A, et al. A study of skin irritations by textiles under standardized sweating conditions in patients with atopic eczema. *Melliand English.* 1995;12:268.
222. Diepgen TL, Stabler A, Hornstein OP. Irritation from textiles in atopic eczema and controls. [German]. *H+G Zeitschrift für Hautkrankheiten.* 1990;65 (10):907-910.
223. Seymour JL, Keswick BH, Hanifin JM, et al. Clinical effects of diaper types on the skin of normal infants and infants with atopic dermatitis. *Journal of the American Academy of Dermatology.* 1987;17 (6):988-997.
224. Oosting AJ, de Bruin-Weller MS, Terreehorst I, et al. Effect of mattress encasings on atopic dermatitis outcome measures in a double-blind, placebo-controlled study: the Dutch mite avoidance study. *Journal of Allergy and Clinical Immunology.* 2002 2002;110(3):500-506.
225. Chinn DJ, Poyner T, Sibley G. Randomized controlled trial of a single dermatology nurse consultation in primary care on the quality of life of children with atopic eczema. *British Journal of Dermatology.* 2002 2002;146(3):432-439.
226. Moore EJ, Williams A, Manias E, et al. Eczema workshops reduce severity of childhood atopic eczema. *Australasian Journal of Dermatology.* May 2009;50(2):100-106.
227. Schuttelaar MLA, Vermeulen KM, Coenraads PJ. Costs and cost-effectiveness analysis of treatment in children with eczema by nurse practitioner vs. dermatologist: results of a randomized, controlled trial and a review of international costs. *British Journal of Dermatology.* 2011;165(3):600-611.
228. Armstrong. Online video improves clinical outcomes in adults with atopic dermatitis: A randomized controlled trial. *Journal of the American Academy of Dermatology.* 2011.
229. Kim SH, Hwang, Sung Hwan, Hong, Soon Kwon, Seo, Jong Keun, Sung, Ho Suk, Park, Sung Wook, Shin, Jeong Hwan. The clinical efficacy, safety and functionality of anion textile in the treatment of atopic dermatitis. *Annals of Dermatology.* 2012.
230. Adachi J, Sumitsuzi H, Endo K, et al. Evaluation of the effect of short-term application of deep sea water on atopic dermatitis. [Japanese]. *Arerugi = [Allergy].* 1998;47 (1):57-60.
231. Melin L, Frederiksen T, Noren P, et al. Behavioural treatment of scratching in patients with atopic dermatitis. *British Journal of Dermatology.* 1986;115 (4):467-474.
232. Ehlers A, Stangier U, Gieler U. Treatment of atopic dermatitis: A comparison of psychological and dermatological approaches to relapse prevention. *Journal of Consulting and Clinical Psychology.* 1995;63 (4):624-635.
233. Salo OP, Gordin A, Brandt H, et al. Efficacy and tolerability of erythromycin acistrate and erythromycin stearate in acute skin infections of patients with atopic eczema. *Journal of Antimicrobial Chemotherapy.* 1988;21 (SUPPL. D):101-106.
234. Weinberg E, Fourie B, Allmann B, et al. The use of cefadroxil in superinfected atopic dermatitis. *Current Therapeutic Research - Clinical and Experimental.* 1992;52 (5):671-676.
235. Ewing CI, Ashcroft C, Gibbs ACC, et al. Flucloxacillin in the treatment of atopic dermatitis. *British Journal of Dermatology.* 1998;138 (6):1022-1029.
236. Larsen FS, Simonsen L, Melgaard A, et al. An efficient new formulation of fusidic acid and betamethasone 17-valerate (fucicort lipid cream) for treatment of clinically infected atopic dermatitis. *Acta Dermato-Venereologica.* 2007 2007;87(1):62-68.
237. Foelster-Holst R, Nagel F, Zoellner P, et al. Efficacy of crisis intervention treatment with topical corticosteroid prednicarbat with and without partial wet-wrap dressing in atopic dermatitis. *Dermatology (Basel, Switzerland).* 2006 2006;212(1):66-69.
238. Hindley D, Galloway G, Murray J, et al. A randomised study of "wet wraps" versus conventional treatment for atopic eczema.[see comment]. *Archives of Disease in Childhood.* 2006 Feb 2006;91(2):164-168.
239. Pei AY, Chan HH, Ho KM. The effectiveness of wet wrap dressings using 0.1% mometasone furoate and 0.005% fluticasone propionate ointments in the treatment of moderate to severe atopic dermatitis in children. *Pediatric Dermatology.* 2001 2001;18(4):343-348.
240. Beattie P, al. e. A pilot study on the use of wet wraps in moderate atopic eczema. British Association of Dermatologists 83rd Annual Meeting. Abstract O-8. *British Journal of Dermatology.* 2003 2003;149(Suppl 64):4.
241. Schnopp C, Holtmann C, Stock S, et al. Topical steroids under wet-wrap dressings in atopic dermatitis--a vehicle-controlled trial. *Dermatology.* 2002 2002;204(1):56-59.
242. Shibagaki N, Inozume T, Ando N, et al. [Clinical efficacy of bath additive containing a diamide derivative in patients with atopic dermatitis]. *Nishinihon Journal of Dermatology.* 2005 2005;67(2):152-159.
243. Harper J. Double-blind comparison of an antiseptic oil-based bath additive (Oilatum Plus) with regular Oilatum (Oilatum Emollient) for the treatment of atopic eczema. *Round Table Series - Royal Society of Medicine.* 1995(37):42-47.
244. Holland KT, Bojar RA, Cunliffe WJ. A comparison of the effect of treatment of atopic eczema with and without antimicrobial compounds. *Round Table Series - Royal Society of Medicine.* 1995;(37):34-41.
245. Huang JT, Abrams M, Tloughan B, et al. Treatment of Staphylococcus aureus colonization in atopic dermatitis decreases disease severity. *Pediatrics.* May 2009;123(5):e808-814.

246. Lintu P, Savolainen J, Kortekangas-Savolainen O, et al. Systemic ketoconazole is an effective treatment of atopic dermatitis with IgE-mediated hypersensitivity to yeasts. *Allergy*. 2001 2001;56(6):512-517.
247. Back, Bartosik J. Systemic ketoconazole for yeast allergic patients with atopic dermatitis.[see comment]. *Journal of the European Academy of Dermatology & Venereology*. 2001 Jan 2001;15(1):34-38.
248. Broberg A, Faergemann J. Topical antimycotic treatment of atopic dermatitis in the head/neck area. A double-blind randomised study. *Acta Dermato-Venereologica*. 1995;75 (1):46-49.
249. Wong AW, Hon EK, Zee B. Is topical antimycotic treatment useful as adjuvant therapy for flexural atopic dermatitis: randomized, double-blind, controlled trial using one side of the elbow or knee as a control. *International Journal of Dermatology*. 2008 2008;47(2):187-191.
250. Anstey A, Wilkinson JD. Lithium succinate ointment in the treatment of atopic eczema[1]. *Journal of Dermatological Treatment*. 1991;2 (1):37-38.
251. Palombo P, Morganti P, Fabrizi G, et al. A special pill-mask to re-hydrate the skin affected by atopic dermatitis. *Journal of Applied Cosmetology*. 2004 2004;22(2):87-97.
252. Stern T, Bayerl C. Black seed oil ointment - A new approach for the treatment of atopic dermatitis? *Aktuelle Dermatologie*. 2002 2002;28(3):74-79.
253. Lee J, Jung E, Koh J, et al. Effect of rosmarinic acid on atopic dermatitis. *The Journal of dermatology*. 2008;35(12):768-771.
254. Thumm EJ, Stoss M, Bayerl C, et al. Randomized trial to study efficacy of a 20% and 10% Hippophae rhamnoides containing creme used by patients with mild to intermediate atopic dermatitis. *Aktuelle Dermatologie*. 2000 2000;26(8-9):285-290.
255. Korting HC, Schollmann C, Cholcha W, et al. Efficacy and tolerability of pale sulfonated shale oil cream 4% in the treatment of mild to moderate atopic eczema in children: a multicentre, randomized vehicle-controlled trial. *Journal of the European Academy of Dermatology & Venereology*. Oct 2010;24(10):1176-1182.
256. Guéniche A, Hennino A, Goujon C, et al. Improvement of atopic dermatitis skin symptoms by Vitreoscilla filiformis bacterial extract. *European journal of dermatology : EJD*. 2006 2006;16(4):380-384.
257. Gueniche A, Knaudt B, Schuck E, et al. Effects of nonpathogenic gram-negative bacterium Vitreoscilla filiformis lysate on atopic dermatitis: a prospective, randomized, double-blind, placebo-controlled clinical study. *British Journal of Dermatology*. 2008 Dec 2008;159(6):1357-1363.
258. Dolle S, Hoser D, Rasche C, et al. Long-term reduction in local inflammation by a lipid raft molecule in atopic dermatitis. *Allergy: European Journal of Allergy and Clinical Immunology*. September 2010;65 (9):1158-1165.
259. Bigliardi PL, Stammer H, Jost G, et al. Treatment of pruritus with topically applied opiate receptor antagonist. *Journal of the American Academy of Dermatology*. 2007 2007;56(6):979-988.
260. Stucker M, Pieck C, Stoerb C, et al. Topical vitamin B12--a new therapeutic approach in atopic dermatitis--evaluation of efficacy and tolerability in a randomized placebo-controlled multicentre clinical trial. *British Journal of Dermatology*. 2004 May 2004;150(5):977-983.
261. Januchowski R. Evaluation of topical vitamin B12 for the treatment of childhood eczema. *J Altern Complement Med*. Apr 2009;15(4):387-389.
262. Bissonnette. Efficacy and safety of topical WBI-1001 in patients with mild to severe atopic dermatitis: results from a 12-week, multicentre, randomized, placebo-controlled double-blind trial. *British Journal of Dermatology*. 2012.
263. Bissonnette R, Chen G, Bolduc C, et al. Efficacy and safety of topical WBI-1001 in the treatment of atopic dermatitis: results from a phase 2A, randomized, placebo-controlled clinical trial. *Archives of Dermatology*. Apr 2010;146(4):446-449.
264. Gandy JJ, Snyman JR, van Rensburg CE, et al. Randomized, parallel-group, double-blind, controlled study to evaluate the efficacy and safety of carbohydrate-derived fulvic acid in topical treatment of eczema. *Clinical, Cosmetic and Investigational Dermatology CCID*. 2011;4:145-148.
265. Misery L, Liege P, Cambazard F. [Evaluation of efficacy and tolerance of a cream containing raffinose during atopic dermatitis]. *Nouvelles Dermatologiques*. 2005 2005;24(5):339-341.
266. Katsuyama M, Masako K, Kobayashi Y, et al. A novel method to control the balance of skin microflora Part 2. A study to assess the effect of a cream containing farnesol and xylitol on atopic dry skin. *Journal of dermatological science*. 2005 2005;38(3):207-213.
267. Arenberger P, Arenbergerova M, Drozenova H, et al. Effect of topical heparin and levomenol on atopic dermatitis: a randomized four-arm, placebo-controlled, double-blind clinical study. *Journal of the European Academy of Dermatology and Venereology : JEADV*. Jun 2011;25(6):688-694.
268. Mora R, Bellussi L, Passali FM, et al. Efficacy of a topical suspension of bacterial antigens for the management of recurrent eczema in children. *Medical science monitor : international medical journal of experimental and clinical research*. 2004 2004;10(9):PI99-PI103.
269. Patzelt-Wenczler R, Ponce-Poschl E. Proof of efficacy of Kamilllosan(R) cream in atopic eczema. *European Journal of Medical Research*. 2000 2000;5(4):171-175.
270. Hamada M, Gyoutoku T, Sato S, et al. The usefulness of camellia oil spray for treatment of atopic dermatitis. [Japanese]. *Nishinihon Journal of Dermatology*. 70(2)(pp 213-218), 2008. Date of Publication: 2008.
271. Wu S.-H. CX-Q, Liu B., Wu H.-J., Dong L. Efficacy and safety of 15(R/S)-methyl-lipoxin A4 in topical treatment of infantile eczema. *British Journal of Dermatology*. 2013.

272. Hashizume E, Nakano T, Kamimura A, Morishita K. Topical effects of N-acetyl-L-hydroxyproline on ceramide synthesis and alleviation of pruritus. *Clinical, cosmetic and investigational dermatology*. 2013.
273. Herzog JL, Solomon JA, Draelos Z, et al. A randomized, double-blind, vehicle-controlled crossover study to determine the anti-pruritic efficacy, safety and local dermal tolerability of a topical formulation (SRD174 cream) of the long-acting opioid antagonist nalmefene in subjects with atopic dermatitis. *Journal of Drugs in Dermatology*. August 2011;10 (8):853-860.
274. Udompataikul. Comparative trial of moisturizer containing licochalcone A vs. hydrocortisone lotion in the treatment of childhood atopic dermatitis: a pilot study. *Journal of the European Academy of Dermatology & Venereology*. 2011.
275. Patrizi A, Raone B, Raboni R, Neri I. Efficacy and tolerability of a cream containing AR-GG27 (sorbityl furfural palmitate) in the treatment of mild/moderate childhood atopic dermatitis associated with pityriasis alba. A double-blind, placebo-controlled clinical trial. *Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia*. 2012.
276. Veien NK, Kaaber K, Larsen PO, et al. Ranitidine treatment of hand eczema in patients with atopic dermatitis: A double-blind, placebo-controlled trial. *Journal of the American Academy of Dermatology*. 1995;32 (6):1056-1057.
277. Schram A. A randomized trial of methotrexate versus azathioprine for severe atopic eczema. *Journal of Allergy and Clinical Immunology*. 2011.
278. HaecK. Enteric-coated mycophenolate sodium versus cyclosporin A as long-term treatment in adult patients with severe atopic dermatitis: A randomized controlled trial. *Journal of the American Academy of Dermatology*. 2011.
279. El-Khalawany MA, Hassan, Shaaban, Dalia, Ghonaim, Noha, Eassa, Bayoumi. Methotrexate versus cyclosporine in the treatment of severe atopic dermatitis in children: a multicenter experience from Egypt. *European journal of pediatrics*. 2013:351 - 356.
280. Pei AY, Chan HH, Leung TF. Montelukast in the treatment of children with moderate-to-severe atopic dermatitis: a pilot study. *Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology*. 2001 2001;12(3):154-158.
281. Yanase DJ, David-Bajar K. The leukotriene antagonist montelukast as a therapeutic agent for atopic dermatitis. *Journal of the American Academy of Dermatology*. 2001 Jan 2001;44(1):89-93.
282. Friedmann PS, Palmer R, Tan E, et al. A double-blind, placebo-controlled trial of montelukast in adult atopic eczema. *Clin Exp Allergy*. Oct 2007;37(10):1536-1540.
283. Veien NK, Busch-Sorensen M, Stausbol-Gron B. Montelukast treatment of moderate to severe atopic dermatitis in adults: a randomized, double-blind, placebo-controlled trial. *Journal of the American Academy of Dermatology*. 2005 Jul 2005;53(1):147-149.
284. Rahman ML, Choudhury AM, Islam MM. Effectiveness of montelukast in the treatment of atopic dermatitis. *Mymensingh Medical Journal: MMJ*. 2006 Jan 2006;15(1):85-88.
285. Capella GL, Grigerio E, Altomare G. A randomized trial of leukotriene receptor antagonist montelukast in moderate-to-severe atopic dermatitis of adults. *European journal of dermatology : EJD*. 2001 2001;11(3):209-213.
286. Pajno GB, Caminiti L, Vita D, et al. Sublingual immunotherapy in mite-sensitized children with atopic dermatitis: a randomized, double-blind, placebo-controlled study. *Journal of Allergy & Clinical Immunology*. 2007 Jul 2007;120(1):164-170.
287. Silny W, Czarnecka-Operacz M. [Specific immunotherapy in the treatment of patients with atopic dermatitis--results of double blind placebo controlled study]. *Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego*. 2006 2006;21(126):558-565.
288. Oldhoff JM, Darsow U, Werfel T, et al. Anti-IL-5 recombinant humanized monoclonal antibody (mepolizumab) for the treatment of atopic dermatitis. *Allergy*. 2005 May 2005;60(5):693-696.
289. Heil PM, Maurer D, Klein B, et al. Omalizumab therapy in atopic dermatitis: depletion of IgE does not improve the clinical course - a randomized, placebo-controlled and double blind pilot study. *Journal der Deutschen Dermatologischen Gesellschaft*. Dec 2010;8(12):990-998.
290. Paul C, Lahfa M, Bachelez H, et al. A randomized controlled evaluator-blinded trial of intravenous immunoglobulin in adults with severe atopic dermatitis [see comments]. *British Journal of Dermatology*. 2002 2002;147(3):518-522.
291. Jee. Long-Term Efficacy of Intravenous Immunoglobulin Therapy for Moderate to Severe Childhood Atopic Dermatitis. *Asthma, Allergy and Immunology Research*. 2011.
292. Wolff K, Fleming C, Hanifin J, et al. Efficacy and tolerability of three different doses of oral pimecrolimus in the treatment of moderate to severe atopic dermatitis: a randomized controlled trial. *British Journal of Dermatology*. 2005 2005;152(6):1296-1303.
293. White CR, Hanifin JM. Levamisole therapy in atopic dermatitis. Randomized double-blind evaluation. *Archives of Dermatology*. 1978;114 (9):1314-1315.
294. Hanifin JM, Schneider LC, Leung DYM, et al. Recombinant interferon gamma therapy for atopic dermatitis. *Journal of the American Academy of Dermatology*. 1993;28 (2 1):189-197.
295. Abeck D, Andersson T, Grosshans E, et al. Topical application of a platelet-activating factor (PAF) antagonist in atopic dermatitis. *Acta Dermato-Venereologica*. 1997;77 (6):449-451.

296. Schmitt J, Sch, x00E, et al. Prednisolone vs. ciclosporin for severe adult eczema. An investigator-initiated double-blind placebo-controlled multicentre trial. *British Journal of Dermatology*. Mar 2010;162(3):661-668.
297. Jang IG, Yang JK, Lee HJ, et al. Clinical improvement and immunohistochemical findings in severe atopic dermatitis treated with interferon gamma. *Journal of the American Academy of Dermatology*. 2000 Jun 2000;42(6):1033-1040.
298. Bemanian MH, Movahedi M, Farhodi A, et al. High doses intravenous immunoglobulin versus oral cyclosporine in the treatment of severe atopic dermatitis. *Iranian Journal of Allergy Asthma & Immunology*. 2005 Sep 2005;4(3):139-143.
299. Diepgen TL, Early Treatment of the Atopic Child Study G. Long-term treatment with cetirizine of infants with atopic dermatitis: a multi-country, double-blind, randomized, placebo-controlled trial (the ETAC trial) over 18 months. *Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology*. 2002 2002;13(4):278-286.
300. Munday J, Bloomfield R, Goldman M, et al. Chlorpheniramine is no more effective than placebo in relieving the symptoms of childhood atopic dermatitis with a nocturnal itching and scratching component. *Dermatology*. 2002 2002;205(1):40-45.
301. Kawashima M, Tango T, Noguchi T, et al. Addition of fexofenadine to a topical corticosteroid reduces the pruritus associated with atopic dermatitis in a 1-week randomized, multicentre, double-blind, placebo-controlled, parallel-group study. *British Journal of Dermatology*. 2003 Jun 2003;148(6):1212-1221.
302. Nakagawa H, Kawashima M. [Efficacy and safety of fexofenadine hydrochloride in pediatric patients with atopic dermatitis in a phase III, randomized, double-blind, multi-center comparative study]. *Nishinihon Journal of Dermatology*. 2006 2006;68(5):553-565.
303. Kawashima. Olopatadine hydrochloride in children: Evidenced efficacy and safety for atopic dermatitis treatment in a randomized, multicenter, double-blind, parallel group comparative study. *Nishinihon Journal of Dermatology*. 2011.
304. Berth-Jones J, Graham-Brown RA. Failure of terfenadine in relieving the pruritus of atopic dermatitis. *British Journal of Dermatology*. 1989;121(5):635-637.
305. Doherty V, Sylvester DG, Kennedy CT, et al. Treatment of itching in atopic eczema with antihistamines with a low sedative profile. *BMJ (Clinical research ed.)*. 1989;298(6666):96.
306. Foulds IS, MacKie RM. A double-blind trial of the H2 receptor antagonist cimetidine, and the H1 receptor antagonist promethazine hydrochloride in the treatment of atopic dermatitis. *Clinical Allergy*. 1981;11(4):319-323.
307. Frosch PJ, Schwanitz HJ, Macher E. A double blind trial of H1 and H2 receptor antagonists in the treatment of atopic dermatitis. *Archives of Dermatological Research*. 1984;276(1):36-40.
308. Hamada T, Ishii M, Nakagawa K, et al. Evaluation of the clinical effect of terfenadine in patients with atopic dermatitis. A comparison of strong corticosteroid therapy to mild topical corticosteroid combined with terfenadine administration therapy. [Japanese]. *Skin Research*. 1996;38 (1):97-103.
309. Hannuksela M, Kalimo K, Lammintausta K, et al. Dose ranging study: Cetirizine in the treatment of atopic dermatitis in adults. *Annals of Allergy*. 1993;70 (2):127-133.
310. Henz BM, Metzner P, O'Keefe E, et al. Differential effects of new-generation H1-receptor antagonists in pruritic dermatoses. *Allergy: European Journal of Allergy and Clinical Immunology*. 1998;53 (2):180-183.
311. Hjorth N. Terfenadine in the treatment of chronic idiopathic urticaria and atopic dermatitis. *Cutis*. 1988;42 (4 A):29-30.
312. Ishibashi Y, Ueda H, Niimura M, et al. Clinical evaluation of E-0659 in atopic dermatitis in infants and children. Dose-finding multicenter study by the double-blind method. [Japanese]. *Skin Research*. 1989;31 (3):458-471.
313. Ishibashi Y, Tamaki K, Yoshida H, et al. Clinical evaluation of E-0659 on atopic dermatitis. Multicenter double-blind study in comparison with ketotifen. *Rinsho Hyoka*. 1989;17(1):77-115.
314. Klein GL, Galant SP. A comparison of the antipruritic efficacy of hydroxyzine and cyproheptadine in children with atopic dermatitis. *Annals of Allergy*. 1980;44 (3):142-145.
315. Langeland T, Fagertun HE, Larsen S. Therapeutic effect of loratadine on pruritus in patients with atopic dermatitis. A multi-crossover-designed study. *Allergy: European Journal of Allergy and Clinical Immunology*. 1994;49 (1):22-26.
316. La Rosa M, Ranno C, Musarra I, et al. Double-blind study of cetirizine in atopic eczema in children. *Annals of Allergy*. 1994;73 (2):117-122.
317. Monroe EW. Relative efficacy and safety of loratadine, hydroxyzine, and placebo in chronic idiopathic urticaria and atopic dermatitis. *Clinical Therapeutics*. 1992;14 (1):17-21.
318. Patel P, Gratton D, Eckstein G, et al. A double-blind study of loratadine and cetirizine in atopic dermatitis. *Journal of Dermatological Treatment*. 1997;8 (4):249-253.
319. Savin JA, Paterson WD, Adam K, et al. Effects of trimeprazine and trimipramine on nocturnal scratching in patients with atopic eczema. *Archives of Dermatology*. 1979;115 (3):313-315.
320. Savin JA, Dow R, Harlow BJ. The effect of a new non-sedative H1-receptor antagonist (LN2974) on the itching and scratching of patients with atopic eczema. *Clinical and Experimental Dermatology*. 1986;11 (6):600-602.
321. Simons FE, Simons KJ, Becker AB, et al. Pharmacokinetics and antipruritic effects of hydroxyzine in children with atopic dermatitis. *Journal of Pediatrics*. 1984;104(1):123-127.

322. Simons FER. Prospective, long-term safety evaluation of the H1-receptor antagonist cetirizine in very young children with atopic dermatitis. *Journal of Allergy and Clinical Immunology*. 1999;104 (2 1):433-440.
323. Wahlgren CF, Hagermark O, Bergstrom R. The antipruritic effect of a sedative and a non-sedative antihistamine in atopic dermatitis. *British Journal of Dermatology*. 1990;122 (4):545-551.
324. Zuluaga de Cadena A, Ochoa de VA, Donado JH, et al. [Comparative study of the effect of the hidroxicina the terfenadina and the astemizol in children with atopic demratitis: Hospital General de Medellin-Centro de Especialistas cE.S. 1986-1988]. *CES med*. 1989;3:7-13.
325. Lee HJ, Park CO, Lee JH, et al. [The antipruritic effect of topical doxepin cream in patients with atopic dermatitis]. *Korean Journal of Dermatology*. 2006 2006;44(3):309-314.
326. Stainer R, Matthews S, Arshad SH, et al. Efficacy and acceptability of a new topical skin lotion of sodium cromoglicate (Altoderm) in atopic dermatitis in children aged 2-12 years: a double-blind, randomized, placebo-controlled trial. *British Journal of Dermatology*. 2005 Feb 2005;152(2):334-341.
327. Malekzad F, Arbabi M, Mohtasham N, et al. Efficacy of oral naltrexone on pruritus in atopic eczema: A double-blind, placebo-controlled study. *Journal of the European Academy of Dermatology and Venereology*. August 2009;23(8):948-950.
328. Kief H. [A prospective, controlled study on the efficacy of the treatment with AHIT and treatment with Patient's blood in atopic dermatitis]. *Aktuelle Dermatologie*. 2007 2007;33(6):216-227.
329. Pittler MH, Armstrong NC, Cox A, et al. Randomized, double-blind, placebo-controlled trial of autologous blood therapy for atopic dermatitis. *British Journal of Dermatology*. 2003 Feb 2003;148(2):307-313.
330. Byun. Full-spectrum light phototherapy for atopic dermatitis. *International Journal of Dermatology*. 2011.
331. Brenninkmeijer EEA, Spuls PI, Lindeboom R, et al. Excimer laser vs. clobetasol propionate 005% ointment in prurigo form of atopic dermatitis: A randomized controlled trial, a pilot. *British Journal of Dermatology*. October 2010;163 (4):823-831.
332. Ebata T, Izumi H, Aizawa H, et al. Effects of nitrazepam on nocturnal scratching in adults with atopic dermatitis: A double-blind placebo-controlled crossover study. *British Journal of Dermatology*. 1998;138 (4):631-634.
333. Ruzicka T. Effect of theophylline in atopic dermatitis: A double-blind cross-over study. *Archives of Dermatological Research*. 1980;269 (1):109-110.
334. Archer CB, Macdonald DM. Treatment of atopic dermatitis with salbutamol. *Clinical and Experimental Dermatology*. 1987;12 (5):323-325.
335. Berth-Jones J, Graham-Brown RA. Failure of papaverine to reduce pruritus in atopic dermatitis: a double-blind, placebo-controlled cross-over study. *British Journal of Dermatology*. 1990;122(4):553-557.
336. Yoshihara S, Fukuda H, Arisaka O, et al. Usefulness of suplatast tosilate, a Th2 cytokine inhibitor based on the Th1/Th2 ratio for allergic disease in children: a retrospective study. *Arzneimittel-Forschung*. 2011:421-424.
337. Kawana S, Kato Y, Omi T. Efficacy of a 5-HT1a receptor agonist in atopic dermatitis. *Clinical & Experimental Dermatology*. Dec 2010;35(8):835-840.
338. Ramirez-Bosca A, Zapater, P., Betlloch, I., Albero, F., Martinez, A., Diaz-Alperi, J., Horga, J. F. Polypodium leucotomos extract in atopic dermatitis: A randomized, double-blind, placebo-controlled, multicenter trial. [Spanish]. *Actas Dermo-Sifiliograficas*. 2012.
339. Pfab. Effect of Acupuncture on Allergen-Induced Basophil Activation in Patients with Atopic Eczema: A Pilot Trial. *The Journal of Alternative and Complementary Medicine*. 2011.
340. Lee. Effectiveness of acupressure on pruritus and lichenification associated with atopic dermatitis: a pilot trial. *Acupuncture in Medicine*. 2012.
341. Senger C, Habermuller M, Revenstorf D. [Hypnotherapy in atopic dermatitis]. *Aktuelle Dermatologie*. 2004 2004;30(4):103-108.
342. Anderson C, Lis-Balchin M, Kirk-Smith M. Evaluation of massage with essential oils on childhood atopic eczema. *Phytotherapy Research*. 2000 Sep 2000;14(6):452-456.
343. Shi YJ, Zhang CM, Ma DM. [Clinical study on treatment of atopic dermatitis by integrated traditional Chinese and Western medicine]. [Chinese]. *Zhongguo Zhong Xi Yi Jie He Za Zhi Zhongguo Zhongxiyi Jiehe Zazhi/Chinese Journal of Integrated Traditional & Western Medicine/Zhongguo Zhong Xi Yi Jie He Xue Hui, Zhongguo Zhong Yi Yan Jiu Yuan Zhu Ban*. 2008 Aug 2008;28(8):686-688.
344. Henderson CA, Morris A, Wilson A, et al. An open study comparing the efficacy of two different Chinese herbal therapy formulations in atopic eczema and their effects on circulating activated T-lymphocytes. *Journal of Dermatological Treatment*. 2000 2000;11(2):91-96.
345. Hon KL, Chan BC, Leung PC. Chinese herbal medicine research in eczema treatment. *Chin Med*. 2011;6:17.
346. Cheng. The Efficacy and Safety of a Chinese Herbal Product (Xiao-Feng-San) for the Treatment of Refractory Atopic Dermatitis: A Randomized, Double-Blind, Placebo-Controlled Trial. *International Archives of Allergy & Immunology*. 2011.
347. Shapira MY, Raphaelovich Y, Gilad L, et al. Treatment of atopic dermatitis with herbal combination of Eleutherococcus, Achillea millefolium, and Lamium album has no advantage over placebo: a double blind, placebo-controlled, randomized trial. *Journal of the American Academy of Dermatology*. 2005 Apr 2005;52(4):691-693.

- Accepted Article
348. Choi IH, Kim, S., Kim, Y., Yun, Y., Choi, In-Hwa, Kim, Sehyun, Kim, YoungChul, Yun, Younghee. The effect of TJ-15 plus TJ-17 on atopic dermatitis: a pilot study based on the principle of pattern identification. *Journal of Alternative & Complementary Medicine*. 2012.
349. Schempp CM, Hezel S, Simon JC. Topical treatment of atopic dermatitis with Hypericum cream. A randomised, placebo-controlled, double-blind half-side comparison study. (German). *Hautarzt*. 2003 2003;54(3):248-253.
350. Sheehan MP, Rustin MHA, Atherton DJ, et al. Efficacy of traditional Chinese herbal therapy in adult atopic dermatitis. *Lancet (London, England)*. 1992;340 (8810):13-17.
351. Sheehan MP, Atherton DJ. A controlled trial of traditional Chinese medicinal plants in widespread non-exudative atopic eczema. *British Journal of Dermatology*. 1992;126 (2):179-184.
352. Fung AYP, Look PCN, Chong LY, et al. A controlled trial of traditional Chinese herbal medicine in Chinese patients with recalcitrant atopic dermatitis. *International Journal of Dermatology*. 1999;38 (5):387-392.
353. Latchman Y, Banerjee P, Poulter LW, et al. Association of immunological changes with clinical efficacy in atopic eczema patients treated with traditional Chinese herbal therapy (Zemaphyte). *International Archives of Allergy and Immunology*. 1996;109 (3):243-249.
354. Schachner L, Field T, Hernandez-Reif M, et al. Atopic dermatitis symptoms decreased in children following massage therapy. *Pediatric Dermatology*. 1998;15(5):390-395.

Supplementary figure 2: Summary of included interventions

Topical treatments		Oral treatments	Other types of treatment
Calcineurin Inhibitors Pimecrolimus (Elidel®) Tacrolimus (Protopic®)	Emollients (branded) A-Derma® Albolene® Aquaphor® Atopiclair™ Axera™ Canoderm® Cetaphil™ EpiCeram® Eucerin® Exomega milk® Hyaltopic™ Lipiderm® Miglyol® MimyX™ Restoraderm® Stelatopia® Tefirax®	Immunosupressants Azathioprine Ciclosporin (Neoral®) Methotrexate Mycophenolate sodium Prednisolone	Immunoglobulins Intravenous immunoglobulin Mepolizumab (intravenous) Omalizumab (subcutaneous)
Corticosteroids Alclometasone dipropionate (Aclovate®) Betamethasone (Betnovate®) Clobetasol propionate (Dermovate®) Clobetasone butyrate (Eumovate®) Desonide hydrogel (Desonate®) Desoximetasone (Topicort®) Fluocinolone acetonide (Derma-Smoothe/FS®) Fluocinonide (Vanos®) Fluticasone propionate (Cutivate®) Hydrocortisone acetate (Hc45®) Hydrocortisone butyrate (Locoid lipocream®) Hydrocortisone solution (Hydrogelan®) Methylprednisolone Aceponate (Advantan®) Mometasone furoate (Elocon®) Prednicarbate Triamcinolone acetonide (Aristocort® A)	Other Topical Atopico® Black seed oil Carbohydrate-derived fulvic acid Cipamfylline Cyanocobalamin Doxepin Hydroxyproline Kamillosan® Lipoxin A4 Miltefosine (Miltex®) Nalmefene (SRD174) Naltrexone Rosmarinic acid Sea buckthorn extract Sensicutan® with heparin and levomenol Shale oil Sodium bituminosulfonate (Ichthosin®) Sodium cromoglycate (Altoderm®) Sorbityl furfural palmitate (AR-GG27®) SRD441 St John’s wort Vitreoquilla filiformis extract WBI-1001	Antihistamines Cetirizine (Zirtek®) Chlorpheniramine (Piriton®) Epinastine hydrochloride Fexofenadine (Telfast®) Ketotifen fumarate (Zaditen®) Loratidine (Claritin®) Olopatadine hydrochloride	Phototherapy Full spectrum light therapy Ultraviolet-A Ultraviolet-B
Corticosteroids with Antibiotics/Antifungals Fusidic acid and betamethasone-17-valerate (Fucicort®) Hydrocortisone and miconazole (Daktacort®) Triamcinolone acetonide and tetracycline		Antifungals Itraconazole Ketoconazole (Nizoral®)	Clothing Ethylene-vinyl alcohol (Mediele®) Silk (Dermasilk®) Silver filaments (Padycare®) Silver coated (X-Static®) Tourmaline coated
Antibiotics/antifungals Ciclopirox olamine (Batrafen®) Fusidic acid (Fucidin®) Mupirocin (Bactroban®)		Other Oral Anapsos® Chinese herbal medicine (various) Hochu-ekki-to Naltrexone Montelukast (Singulair®) Pimecrolimus Tandospirone citrate	Interaction-based Additional visits to healthcare professionals Educational E-health portal Psychological Support groups
Bathing-related Eucalyptus and oat extract mixture bath additive Sodium hypochlorite (bleach) bath additive Triclosan (Safeguard®) soap bar		Dietary Borage oil Evening primrose oil Fish oil Hempseed oil Milk replacements Prebiotics Probiotics Synbiotics Vitamin D2 and D3 Vitamin E	Complementary Acupuncture Acupressure Aromatherapy and massage Hypnotherapy Progressive muscle relaxation
Emollients (unbranded) Farnesol and xylitol-containing Furfuryl palmitate-containing Glycerine-containing Triclosan-containing leave-on emollient Urea-containing			Enviromental Balneotherapy House dust mite reduction Ion-exchange water softeners Visiting a different climate